Sughrue
SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, DC 20037-3213
T 202.293.7060
F 202.293.7860
www.sughrue.com

March 29, 2002

BOX PCT
Commissioner for Patents
Washington, D.C. 20231

PCT/JP00/06804
-filed September 29, 2000

Re: Application of Kei YAMANA, Yukimi NAGASAWA, Hitoshi WADA and Yoshinori KASAHARA
A NOVEL POLYPEPTIDE AND GENE ENCODING THE SAME
Assignee: TEIJIN LIMITED
Our Ref: Q69170

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. § 371 and in accordance with Chapter II of the Patent Cooperation Treaty:

- ☑ an executed Declaration and Power of Attorney.
- ☑ an English translation of the International Application.
- ☑ ten (10) sheets of drawings.
- ☑ an executed Assignment and PTO 1595 form.
- ☑ twenty (20) pages of Sequence listing and a 3.5" disk containing Sequence Listing.
- ☑ Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825.
- ☑ International Search Report, Information Disclosure Statement a Form PTO-1449.

It is assumed that copies of the International Application, the International Search Report, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by § 371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned can easily provide them upon request.

Applicants note that the second inventor's name changed from Yukimi Takahashi to Yukimi Nagasawa due to marriage. A Declaration is being prepared in this regard and will be filed with a Petition after it is executed.

The Government filing fee is calculated as follows:

Total claims	69	-	20	=	49	x	$18.00	= $882.00
Independent claims	6	-	3	=	3	x	$84.00	= $252.00
Base Fee								$890.00
Multiple Dependent Claim Fee								$280.00
TOTAL FILING FEE								$2304.00
Recordation of Assignment								$ 40.00
TOTAL FEE								$2344.00

Checks for the statutory filing fee of $2304.00 and Assignment recordation fee of $40.00 are attached. You are also directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.492 which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

Priority is claimed from:

Country	Application No	Filing Date
Japan	11-275947	September 29, 1999

Respectfully submitted,

Susan J. Mack / Bruce E. Kramer Reg. No. 33,725

Susan J. Mack
Registration No. 30,951

SJM/amt

Description

A Novel polypeptide and gene encoding the same

Field of the Invention

The present invention relates to a novel human, mouse and rat polypeptide having a homology in the amino acid sequence with chondromodulin-I (ChM-I) that is known to have an effect of controlling the growth and differentiation of chondrocytes and inhibiting angiogenesis, and a human, mouse and rat gene (hereinafter referred to as "ChM1L gene") encoding the same.

Background Art

Almost all the bones of mammals are formed through a mechanism called "endochondral bone formation" in which chondrocytes calcify via the growth and differentiation thereof, and are finally replaced with bone. It is known that a variety of hormones and growth factors participate in this series of process, including insulin-like growth factor (IGF1, IGF2), fibroblast growth factor (FGF), transforming growth factor (TGF), growth hormone and the like. Hiraki et al. isolated ChM-I gene as a factor, in addition to the above hormones and growth factors, that facilitates the growth and differentiation of chondrocytes (Biochem. Biophys. Res. Commun., 175, 971-977, 1991, European Patent Publication No. 473080). Human ChM-I is synthesized as a type II membrane protein comprising 334 amino acid residues and, after glycosylation, undergoes processing with a result that the C-terminal portion comprising 120 amino acid residues are extracellularly secreted (Hiraki et al., Eur. J. Biochem. 260, 869-878, 1999). ChM-I not only promotes the growth of cultured chondrocytes but potently promotes proteoglycan synthesis and the colony formation of chondrocytes in agarose (Inoue et al., Biochem. Biophys.

Res. Commun., 241, 395-400, 1997). ChM-I also promotes the growth of osteoblasts (Mori et al., FEBS Letters, 406, 310-314, 1997).

On the other hand, it has long been pointed out that cartilage remains not only avascular but resistant to infiltration of blood vessels. Hiraki et al. attempted to purify a growth inhibiting factor for vascular endothelial cells from the extracts of cartilaginous tissue, and have succeeded in the complete purification thereof. As a result, it was found to be ChM-I (Hiraki et al., FEBS Letters, 415, 321-324, 1997; Hiraki et al., J. Biol. Chem., 272, 32419-32426, 1997). Generally, the cartilaginous tissue is characterized by being avascular, but in the replacement to the bone tissue, it is believed, infiltration of blood vessels into the cartilaginous tissue is required. In the scheduled region of vascular invasion, the hypertrophy of cartilaginous tissue and the calcification of cartilage matrix occur prior to vascular invasion to be ready for forming the primary point of ossification. In the region where the hypertrophic cartilage and the subsequent ossified cartilage appear, the expression of ChM-I dramatically decreases. Thus, although the expression of the ChM-I gene is cartilage-specific, it is limited to the avascular cartilage that is resistant to vascular invasion. As described above, it is believed that ChM-I not only promotes the growth, differentiation, and maturing of cartilage but inhibits the infiltration of blood vessels by inhibiting the growth of vascular endothelial cells. Thus, the expression in the avascular cartilage and the disappearance of expression in the ossified layer prior to vascular invasion are in good agreement with the bifunctional effect of ChM-I.

In the cartilaginous tissue, bFGF that is a potent angiogenic factor is accumulated in pericellular space in large quantities, and it has been elucidated that ChM-I is present in interterritorial space in such a way as to

surround bFGF (Hiraki et al., J. Biol. Chem., 272, 32419-32426, 1997). Thus, in the avascular cartilage, ChM-I is present in a form that masks the angiogenic factor, and it is thought that the angiogenenic effect of ChM-I may account for the absence of blood vessels in the cartilage (Tanpakusitsu kagaku koso, Vol. 40, No. 5, 1995). It has also been confirmed that ChM-I suppresses the growth of tumor cells by inhibiting the infiltration of blood vessels into human tumor cells in vivo (Hayami et al., FEBS Letters, 458, 436-440, 1999). The expression analysis of ChM-I in various mouse tissues revealed that ChM-I is expressed in the eye and the thymus in addition to the cartilage, but the function of ChM-I in these tissues has yet to be elucidated (Shukunami et al., Int. J. Dev. Biol. 43, 39-49, 1999).

The growth and the expression of differentiation function of chondrocytes plays an important role in the healing process from fracture or various cartilage diseases. Thus ChM-I, a factor that promotes the growth and differentiation of chondrocytes, is a promising candidate for an agent that promotes the growth of chondrocytes (Kokai (Japanese Unexamined Patent Publication) No. 7-138295). In the growth or metastasis of tumor cells, infiltration of blood vessels into tissues is required to obtain energy necessary therefor. Therefore ChM-I that has an effect of inhibiting angiogenesis is also a likely candidate for an anti-cancer agent (Kokai (Japanese Unexamined Patent Publication) No. 7-138295). As described above, ChM-I not only controls the growth and differentiation of chondrocytes but inhibits angiogenesis, and hence its application into drugs is being awaited.

In recent years, biotechnology has made rapid progress, and in association with the development of the human genome project as well, a great number of new genes are being cloned. It is said that the number of human genes amounts to about 100,000, and among the genes

groups of molecules having a homology in the amino acid sequences sometimes form families. As the groups of molecules having a homology in the amino acid sequences, various gene families are known such as the TNF family, the TNF receptor family, the chemokine family, G-protein coupled receptor family and many other gene families. For example, as the molecules belonging to the TNF family, there are known about 20 molecules including tumor necrosis factor α (TNFα, Pennica et al., Nature 312, 724, 1984), Fas ligand (FasL, Suda et al., Cell 75, 1167, 1993), TNF-related apoptosis-inducing ligand (TRAIL, Steven et al., Immunity 3, 673, 1995), B lymphocyte stimulator (BLYS, Moore et al., Science 285, 260-263, 1999), and the like.

The molecules belonging to the TNF family are type II membrane proteins and have a homology in the amino acid sequence in the extracellular region. Although homology in the amino acid sequence is noted, these molecules have been demonstrated to have their inherent functions, and their application as pharmaceutical agents have been attempted in a variety of diseases. It has also been shown that the molecules of the TNF family have their unique receptors, and the application thereof as pharmaceutical agents have also been attempted. In fact, some have been approved as pharmaceutical products (for example, soluble TNF receptor, by Immunex). Research and development is also in progress on antibodies against these molecules as pharmaceutical drugs, and in fact, some have been approved as pharmaceutical products (for example, anti-TNF-α antibody, by Centocore). As examples of molecules having a homology in the amino acid sequence that were applied into the development of pharmaceutical products, the TNF family and the TNF receptor family were illustrated as above. Some of the underlying reasons that enabled the application of these molecules into pharmaceutical products are the facts that

the functions of each of these molecules were analyzed and the similarity and the difference between them were elucidated.

Molecules of the TNF family have the structure of type II membrane proteins and since many of them are expressed mostly in the blood system and the lymphatic system, they have a lot in common in terms of experimental techniques and samples. It is therefore expected that when a new gene belonging to the TNF family was discovered, the speed at which its function was analyzed must have been faster than the molecules discovered earlier. Thus, the discovery of a novel gene having a homology in the amino acid sequence and the analysis of its function would not only facilitates the functional analysis of novel genes to be discovered in the future but the result of analysis permits its comparison with the existing molecules, and therefore it is expected that more detailed findings on the functions of the existing molecules could be obtained.

Generally, when a novel gene encoding a protein having a homology in the amino acid sequence with existing molecules is cloned, the techniques and materials to be used for functional analysis may be referred to the examples of the existing molecules. However, even a molecule having a homology in the amino acid sequence is thought to have its own unique function as in the above-mentioned TNF family, and thus when its application into pharmaceutical products is envisaged, it is necessary to demonstrate the expression and purification of the recombinant protein, the generation of antibody, the expression of mRNA and protein at various tissues and the like, and thereby to clarify the difference in the structure and function from the existing molecules.

Disclosure of the Invention

Thus, it is an object of the present invention to

provide a new polypeptide similar to ChM-I and a gene encoding the same. It is also an object of the present invention to implement the generation of antibody against said polypeptide, the analysis of expression levels of said gene and the polypeptide, the expression and structural analysis of the recombinant protein and the like in order to clarify its similarity and difference with ChM-I, and to elucidate the function so as to enable the elucidation of pathological states, diagnosis, treatment etc. of diseases in which they are involved.

ChM-I is a type II membrane protein that regulates the growth and differentiation of chondrocytes and inhibits angiogenesis, and is a promising candidate for application into pharmaceutical products. Thus, once a gene encoding a new polypeptide similar to ChM-I has been provided, it is believed, its expression level in various cells and its structure and function can be analyzed, and the analysis of the expression products would enable the elucidation of pathology, diagnosis and treatment etc. of diseases in which they are involved. At present, however, there are no reports on molecules having a homology with the amino acid sequence of ChM-I, and it is unknown whether ChM-I forms a gene family or not. Thus, if a new polypeptide similar to ChM-I and a gene encoding the same are shown to be present, the analysis of structure, function etc. thereof would permit the study on its similarity and difference with ChM-I, which in turn would accelerates the elucidation of physiological functions of the molecules with one another, the elucidation of pathological states in which these molecules are involved, diagnosis, the development of therapeutic agents and the like.

After intensive and extensive research to attain the above purposes, the inventors of the present invention have succeeded in isolating a gene (ChM1L gene) that meets the above purposes, from human, mouse and rat cDNA libraries, and carried out the analysis of its expression

level in various tissues, the generation of an antibody against said polypeptide, the expression of a polypeptide encoded by said gene in a mammalian cell, its detection and purification and the like, demonstrating that said polypeptide has an effect of inhibiting angiogenesis, and we hereby have completed the present invention.

Thus, the present invention is a gene encoding a polypeptide that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2, 4, and 6. As the above gene, there can be mentioned the nucleotide sequence represented by SEQ ID NO: 1, 3, and 5.

Furthermore, the present invention is a polypeptide encoded by a human, mouse and rat gene which polypeptide substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2, 4 and 6.

The present invention is also an oligonucleotide probe that hybridizes to at least part of the above gene.

The present invention is also a recombinant DNA comprising the above gene.

The present invention is also a transformant transformed with the above recombinant DNA.

The present invention is also a method of producing the above polypeptide which method comprises culturing the above transformant and harvesting a polypeptide encoded by the gene of the present invention from the culture.

The present invention is also a monoclonal antibody or polyclonal antibody that specifically reacts with the above polypeptide.

The present invention is also a hybridoma that produces the above monoclonal antibody that is obtained by fusing an antibody-producing cell immunized with the above polypeptide to a myeloma cell.

The present invention is also a reagent for detecting genes said reagent comprising the above oligonucleotide probe.

The present invention is also a diagnostic kit that

comprises the above polypeptide and the above monoclonal antibody or polyclonal antibody.

The present invention is also a pharmaceutical composition comprising a polypeptide encoded by the gene that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2, 4, or 6.

The present invention is also a pharmaceutical composition comprising a monoclonal antibody or a polyclonal antibody that specifically reacts with the above polypeptide.

The present invention is also a pharmaceutical composition comprising an antisense oligonucleotide that specifically hybridizes to part of the above gene.

The present invention is also a pharmaceutical composition comprising a nucleic acid that can be used in gene therapy said composition comprising at least part of the above gene.

The present invention is also a polypeptide wherein the above polypeptide is a membrane-bound form.

The present invention is also a gene encoding the above membrane-bound polypeptide.

The present invention is also a gene wherein the above human gene is present on chromosome X.

The present invention is also a polypeptide wherein the above polypeptide has an effect of inhibiting angiogenesis.

The present invention is also a gene encoding the above polypeptide that has the above effect of inhibiting angiogenesis.

Brief Explanation of the Drawings

Figure 1A is a result in which the homology of amino acid sequences of human ChM1L and human ChM-I were compared.

Figure 1B is a result in which the homology of amino acid sequences of human, mouse and rat ChM1L were compared.

Figure 2 shows a hydrophobic profile of the amino acid sequences of human ChM-I, human ChM1L, and mouse ChM1L.

Figure 3 shows the result of expression analysis of ChM1L mRNA in various tissues of adult and fetal mice, and the expression analysis of ChM1L and ChM-I mRNA in the developmental stage of a fetal mouse.

Figure 4 shows a result in which human and mouse ChM1L proteins were expressed in COS7 cells and detected by Western blot. (a) shows the result in which Mock (lane 1), human ChM1L (lane 2), and mouse ChM1L (lane 3) were transfected, and the cellular components were subjected to electrophoresis and stained with Coomassie brilliant blue; (c) shows the result in which the same samples as above were detected by Western blot using anti-ChM1L peptide antibody; (b) shows the result in which Mock (lane 1), human ChM1L (His-tagged) (lane 2), and mouse ChM1L (His-tagged) (lane 3) were transfected, and the cellular components were electrophoresed and stained with Coomassie brilliant blue; (d) shows the result in which the same samples as above were detected by Western blot using anti-His tag antibody.

Figure 5 shows the result in which soluble ChM1L (lane 2) and Mock (lane 1) expressed in COS7 cells were detected by Western blot using anti-FLAG M2 antibody.

Figure 6 shows the result in which mouse ChM1L (His-tagged) protein was expressed in COS7 cells, and after the cellular components were recovered they were subjected to a deglycosylation, and the ChM1L protein was detected by Western blot using anti-His tag antibody followed by the analysis of glycosylations. Lane 1 represents the result of Western blot of a non-treated sample, lane 2 represents that of a NANase II + O-glycosidase DS + PNGase-treated sample, lane 3 represents that of a NANase II-treated sample, lane 4 represents that of an O-glycosidase DS-treated sample, and lane 5 represents that of a PNGase-treated sample.

Figure 7 shows the result in which the expression of ChM1L protein in mouse rib cartilage was detected by immunostaining using anti-ChM1L polypeptide antibody.

Figure 8 shows the result in which a soluble human ChM1L protein that was expressed in the culture liquid of COS7 cells was purified by affinity chromatography using anti-FLAG M2 affinity gel, electrophoresed, and stained with Coomassie brilliant blue. Lane 1 shows the result of electrophoresis of the culture supernatant of COS7 cells and lane 2 shows that of the purified ChM1L protein.

Figure 9 shows the result in which the tube-like structure-forming system of the human umbilical vein endothelial cells were treated with (a) the buffer alone, (b) 20 μg of bovine serum albumin (BSA), (c) 10 μg of soluble human ChM1L, (d) 20 μg of soluble human ChM1L, (e) 1 μg of platelet factor 4 (PF-4), and (f) 10 μg of PF-4.

Best Mode for Carrying Out the Invention

In accordance with the present invention, "substantially comprise" means that the gene or polypeptide of the present invention, as long as it retains its function, may have mutations such as substitution, insertion, or deletion in the nucleotide sequence as set forth in SEQ ID NO: 1, 3, or 5 or the amino acid sequence as set forth in SEQ ID NO: 2, 4, or 6.

The ChM1L gene sequence of the present invention may be obtained by the RACE method (RACE: Rapid amplification of cDNA ends; Frohman, M. A. et al., Proc. Natl. Acad. Sci. USA, 85, 8998-9002, 1988), the outline of which method is as follows:

Generally, the RACE method enables one to obtain a full-length cDNA in an efficient manner, when a portion of a cDNA sequence is known. Primers are constructed

from known sequence regions to permit elongation in each of the 3'-end or 5'-end direction, and then cDNA is amplified by the polymerase chain reaction (PCR, Science, 230, 1350-1354, 1985). When a PCR method is carried out, primers that specifically anneal are used in the known region, and primers that anneal to the sequence tagged by a ligation reaction are used in the 3'-end and the 5'-end. Thus, the regions amplified by PCR contain unknown regions. The isolation and purification of the amplified cDNA fragment can be performed according to a standard method as described below, for example gel electrophoresis may be employed. The determination of nucleotide sequence of the DNA fragment thus obtained may be performed according to a standard method such as the dideoxy method (Proc. Natl. Acad. Sci. USA, 74, 5463-5467, 1977) and the Maxam-Gilbert method (Methods in Enzymology, 65, 499, 1980). Such determination of nucleotide sequences may also be carried out using commercially available sequencing kits, etc.

More specifically, it is outlined as follows, though more detailed explanations thereof will be made hereinafter in Example 2. Using the amino acid sequence of human ChM-I, TBLASTN search was performed for the EST data base (dbEST, EST: Expressed sequence tag) in the DNA data bank of Japan (DDBJ) to detect an EST file, GenbanK accession number AI123839. AI123839, which is a nucleotide sequence fragment registered in dbEST, was found for the first time by the above TBLASTN search to be a novel gene fragment encoding an amino acid sequence similar to ChM-I. Thus, primers were synthesized from part of the sequence of cDNA obtained from dbEST, and the sequence of human ChM1L gene was determined using the RACE method. Subsequently, the sequences of mouse and rat ChM1L genes were similarly determined. The sequences of human, mouse and rat ChM1L genes are shown in SEQ ID NO: 1, 3 and 5, and the amino acid sequences of the peptides encoded thereby are shown in SEQ ID NO: 2, 4 and

6.

The polypeptides encoded by the ChM1L genes of the present invention are composed of 317 amino acids (SEQ ID NO: 2, 4 and 6). The amino acid sequence of ChM1L has a homology with ChM-I, in particular a very high homology with the C-terminal portion that is extracellularly secreted after the processing of ChM-I (Figure 1(a)). The amino acid sequences of ChM1L have a very high homology in between humans, mice, and rats (Figure 1(b)). From the hydrophobicity analysis of the amino acid sequence, ChM1L similarly to ChM-I is thought to be a molecule having the structure of the type II membrane proteins (Figure 2). As shown in Figure 2, in both of said polypeptide and ChM-I, a hydrophobic domain comprising about 20 amino acids that is uniquely found in molecules having a membrane-binding activity is present in the vicinity of several dozen amino acids from the N-terminal. That said polypeptide is a molecule having the type II membrane protein structure was also demonstrated by the result in Example 8 in which said polypeptide was expressed in COS7 cells (Figure 4).

The human ChM1L gene of the present invention was shown, as described below in Example 12, to be present on chromosome X (GenbanK accession No. AL035608).

As the ChM1L gene of the present invention, there can be mentioned cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA and combinations thereof. Using a standard method, said genomic DNA may also be isolated by hybridization with the ChM1L gene that is disclosed herein. RNA that was transcribed from said ChM1L gene is also encompassed in the present invention. The sequences of the gene of the present invention represented by SEQ ID NO: 1, 3 and 5 are a combination example of codons representing amino acid residues encoded by them. The ChM1L gene of the present invention is not limited to this, and it is also possible to have a DNA sequence obtained by combining codons to amino acid

residues and then selected. The selection of said codon may be performed according to a standard method, and for example the frequency of use of host's codons to be used is taken into account (Nucleic Acids Research, 9, 43-74, 1981).

Furthermore, the ChM1L gene of the present invention encompasses DNA sequences encoding mutants in which parts of the amino acid sequence as set forth in SEQ ID NO: 2, 4, and 6 are substituted, deleted, or added. The production, modification (mutation) and the like of these polypeptides may naturally occur, and can be obtained by post-translational modification or by a genetic engineering method such as site-specific mutagenesis (Methods in Enzymology, 154, 350, 367-382, 1987; ibid., 100, 468, 1983; Nucleic Acids Research, 12, 9441, 1984; Zoku Seikagaku Jikken Koza 1 (Sequel to Biochemistry Experimental Series 1) "Idensi Kenkyuuhou II (Gene Study Method II)", edited by The Japanese Biochemical Society, 105, 1986) and the like.

The production of the ChM1L gene of the present invention may be readily performed by a common genetic engineering method based on the sequence information of the ChM1L gene of the present invention (Molecular Cloning, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989; Zoku Seikagaku Jikken Koza (Sequel to Biochemistry Experimental Series) "Idensi Kenkyuuhou I, II, III (Gene Study Method I, II, III)", edited by The Japanese Biochemical Society, 1986).

This can be attained by, for example, selecting the desired clones from a cDNA library (prepared from a suitable cell source that expresses the ChM1L gene according to a standard method) using suitable probes and antibodies unique to the gene of the present invention (Proc. Natl. Acad. Sci. USA, 78, 6613, 1981; Science, 222, 778, 1983, and the like).

In the above method, as the cell source, there can be illustrated various cells, tissues, and cultured cells

derived therefrom and the like that express the ChM1L gene, from which any of separation of total RNA, separation and purification of mRNA, and conversion (synthesis) into cDNA, cloning etc. may be performed according to a standard method. cDNA libraries are commercially available, and in the present invention, these cDNA libraries such as various cDNA libraries commercially available from Clontech can be used.

The screening of the ChM1L gene of the present invention from a cDNA library may be carried out according to the above standard method. As the above screening method for, for example a polypeptide produced by cDNA, there can be illustrated a method of selecting a corresponding cDNA clone by immunological screening using a specific antibody against a polypeptide encoded by the ChM1L gene of the present invention, a plaque hybridization method using a probe that selectively binds to the nucleotide sequence of interest, a colony hybridization method and the like as well as combinations thereof. Probes that may be used herein include a DNA sequence that was chemically synthesized based on the information on the DNA sequence of the ChM1L gene of the present invention, the ChM1L gene of the present invention that was already obtained and fragments thereof.

In order to obtain the ChM1L gene of the present invention, a PCR method for amplifying DNA/RNA can be preferably used. Primes for use in such a method can be appropriately selected based on the sequence information of the ChM1L gene of the present invention that was elucidated for the first time by the present invention, and can be synthesized according to a standard method.

More specifically, it is outlined as follows, though more detailed explanations thereof will be made hereinafter in Example 2. A primer is synthesized so as to contain the coding sequence of the ChM1L gene, and the it is used to amplify the ChM1L gene using a PCR method.

Then, it is electrophoresed and the band of interest is excised, from which DNA is purified. The purified DNA and the plasmid vector are ligated and transformed into Escherichia coli (E. coli). Subsequently, the plasmid is purified from the E. coli culture liquid and the integration of the sequence of interest is confirmed using a DNA sequencer. The ChM1L gene thus cloned can be transferred to other plasmid vectors or virus vectors using suitable restriction enzymes.

Using the ChM1L gene (cDNA and genomic DNA) thus obtained, it is possible to create a genetically modified animal in which the expression of the ChM1L gene is increased, decreased, or lost by a standard method.

Based on the sequence information of the ChM1L gene of the present invention, the expression of the ChM1L gene of the present invention in various tissues can be detected using part or all of the nucleotide sequence of said gene. This can be advantageously accomplished according to standard methods such as the RT-PCR (reverse transcribed-polymerase chain reaction) (Kawasaki, E.S., et al., Amplification of RNA. In PCR Protocol, A Guide to methods and applications, Academic Press, Inc., SanDiego, 21-27, 1989) method, Northern blotting analysis (Molecular Cloning, Cold Spring Harbor Laboratory, 1989) and the like. Primers for the RT-PCR method and probes for Northern blotting analysis are not limited, as long as they are the sequences capable of specifically detecting the ChM1L gene, and such sequences can be appropriately determined based on the nucleotide sequence of the ChM1L gene of the present invention. Thus, the present invention provides primers and/or probes useful for the detection of the ChM1L gene. The above probes may also be used for the detection of genomic DNA by Southern blotting analysis.

As means to detect the expression of ChM1L mRNA, there can be illustrated the RT-PCR method described in Example 6. It is outlined as follows, though more

detailed explanations thereof will be made hereinafter in Example 6.

After extracting each tissue and extracting RNA therefrom, it is subjected to a reverse transcription reaction to synthesize cDNA. Using this cDNA as a template, a PCR reaction is carried out, and the reaction mixture obtained is subjected to electrophoresis on agarose gel. Examining the band under UV irradiation, the amount of the ChM1L gene expressed in each tissue was detected. As a result, the expression of ChM1L mRNA in each tissue of an adult mouse was observed in the brain, the eyeball, the skeletal muscle, the whole rib and the thyroid (Figure 3(a)). On the other hand, the expression of ChM-I mRNA in the mouse has been confirmed in the eyeball, the thymus, the cartilage and the whole rib (Shukunami et al., J. Dev. Biol. 43, 39-49, 1999). Thus, it was revealed that ChM1L and ChM-I are expressed at different tissues in the living body, and thus their physiological functions were considered to be different. The expression of ChM1L was observed even at tissues such as the brain, the skeletal muscle, and the thyroid in which no expression of ChM-I has been confirmed.

Since ChM1L is also expressed in the eyeball that is a tissue in which ChM-I expression has been observed and that is resistant to vascular invasion and the whole rib containing cartilage, ChM1L is thought to be involved in angiogenesis. These results suggest that ChM1L may be associated with brain-related diseases such as Alzheimer's disease, skeletal muscle-related diseases such as muscular dystrophy, thyroid-related diseases such as Basedow's disease, eyeball-related diseases such as diabetic retinopathy, cartilaginous tissue-related diseases such as osteoarthritis and rheumatoid arthritis, and angiogenesis-related diseases such as cancer. Thus, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, agents that promote or

reduce the expression of the ChM1L gene, and the like are considered to be used as therapeutic agents for these diseases. The agonists and antagonists mentioned above are intended to include peptides, proteins, low molecular weight compounds and the like, but the physical properties are not limited to them as long as they retain the function.

In various tissues of a fetus, the expression of ChM1L mRNA was noted in the eyeball, the kidney, the stomach, the whole rib and the trachea (Figure 3(b)). In an adult mouse, ChM1L mRNA was not expressed in the kidney or the stomach, but the ChM1L mRNA was expressed in these tissues of the fetus suggests that ChM1L is involved in the development and morphogenesis of these organs. Thus, ChM1L is thought to be also associated with the repair and regeneration of these organs in adults. It was also revealed that ChM1L mRNA is expressed in the trachea. Thus, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, agents that promote or reduce the expression of the ChM1L gene, and the like are considered to be used as therapeutic agents for kidney-related diseases such as chronic kidney failure, stomach-related diseases such as gastric cancer and gastric ulcer, and trachea-related respiratory diseases such as chronic bronchitis and asthma.

In the developmental stage of the fetus, the expression of ChM1L mRNA is very weak at day 10 of gestation, and the expression increases at around days 11 to 13 (Figure 3(c)). On the other hand, though ChM-I, similarly to ChM1L, increases in expression with the development of the fetus, it was evidently expressed more strongly than ChM1L on days 10 and 11 of gestation. It is, therefore, clear that ChM1L lags behind ChM-I in the expression, and that these molecules have different functions in the development of the fetus. The increase

in ChM1L expression in the developmental stage of the fetus suggests that ChM1L is deeply involved in the generation of organs and the skeleton. Thus, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, agents that promote or reduce the expression of the ChM1L gene, and the like are considered to be used as agents for regenerating and repairing organs in the case of congenital diseases associated with inadequate development of the organs or acquired damages to the organs. Furthermore, since there are differences between ChM1L and ChM-I in the expression in various tissues in the adult and the fetus, and in the expression during the developmental stage of the fetus, it is expected that these molecules and drugs that target these molecules, when used as therapeutic agents, have different uses.

Using the sequence of the ChM1L gene of the present invention, it is possible to produce a polypeptide encoded by said gene by a gene engineering method.

The production of the above polypeptide may be performed by constructing a recombinant DNA that permits the expression of the ChM1L gene of the present invention in a host cell, introducing this into a host cell to transform it and then cultivating said transformant.

As the host cell, any of eukaryotic cells and prokaryotic cells can be used.

As the above eukaryotic cells, there may be mentioned vertebrates, yeasts, insect cells, and the like. As the vertebrate cells, there may be mentioned CHO cells, COS cells, and the like.

As the expression vector for vertebrates, there can be used those that have a promoter generally located upstream of the gene to be expressed, a polyadenylation site, a transcription termination sequence, and the like. As the above expression vector, for example there can be illustrated pSV2dhfr (Mol. Cell. Biol., 854, 1981),

pcDNA3.1(+) (Invitrogen) and pCAGGS (Gene, 108, 193-200, 1991) that have the SV40 early promoter.

As means to express the polypeptide of interest in a eukaryotic cell, there are many systems known per se in the field of art.

For example, as a system that allows expression in yeasts, there can be mentioned "Expression of polypeptides in yeast" described in Kokai (Japanese Unexamined Patent Publication) No. 57-159489, as a system that allows expression in insect cells, there can be mentioned "Process for producing a recombinant baculovirus expression vector" described in Kokai (Japanese Unexamined Patent Publication) No. 60-37988, and as a system that allows expression in mammalian cells, there can be mentioned "Improvement of eukaryotic expression" described in Kokai (Japanese Unexamined Patent Publication) No. 2-171198, and there are many others.

The ChM1L gene of the present invention can also be expressed in prokaryotic host cells such as E. coli, Bacillus subtilis, and Streptomyces. For E. coli as above host cell, Escherichia coli strain K12 is often used, and as the vector pBR322 and improved vectors thereof are often used, but they are not limiting and many other known microbial stains and vectors may be used. As the promoter, for example, there can be mentioned, but not limited to, promoters such as E. coli lactose (lac) and E. coli trp. All of the above promoters have already been characterised and are well known to a person skilled in the art, and can be assembled either synthetically or from known plasmids.

The illustrated DNA sequence of the present invention, plasmids and viruses may have many modifications and variations. For example, due to degeneracy of genetic code, nucleotide substitution can be made throughout the coding region of a polypeptide. Such a sequence can be easily deduced from the nucleotide

sequence of ChM1L gene of the present invention or the amino acid sequence encoded by the gene, and can be assembled by a conventional synthetic method described below. Such a synthetic method may be substantially carried out according to Itakura's method (Itakura et al., Science, 198, 1059, 1977) and Crea's method (Crea et al., Proc. Natl. Acad. Sci. USA 75, 5765, 1978). Thus the present invention is not limited to the specifically illustrated nucleotide sequences, plasmids or viruses.

As methods of introducing the desired recombinant DNA of the present invention into a host cell and the following transforming method, various conventional methods may be used. The transformant obtained may be cultured according to a standard method, from which culture the polypeptide encoded by the ChM1L gene of the present invention can be produced. As the culture medium used for this culturing, a commonly used medium may be selected as appropriate depending on the host cell adopted, and culturing may be carried out under a condition suitable for the growth of the host cell.

From the foregoing, the above polypeptide can be produced intracellularly, extracellularly, or on the cell membrane of the transformant. Said polypeptide can be separated and purified utilizing, as desired, the physical properties, chemical properties thereof or the like by various separation procedures ["Biochemistry Databook II", pp. 1175-1259, First edition, First Print, June 23, 1980, Tokyo Kagaku Dojin; Biochemistry, 25(25), 8274-8277 (1986); Eur. J. Biochem., 163, 313-321 (1987), and the like]. Specific examples of said methods include, for example, commonly used reconstitution treatment, treatment with a polypeptide precipitating agent (salting out), centrifugation, osmotic shock, ultrasonic disruption, ultrafiltration, gel filtration, various chromatographic methods such as adsorption chromatography, ion exchange chromatography, affinity chromatography and high performance liquid chromatography

(HPLC), and combinations thereof. Furthermore, by allowing the expression of the protein in which an affinity tag was fused to said polypeptide, the tag can be used to perform affinity purification. As the affinity tag as used herein, there can be mentioned a polyhistidine tag (His tag, Sisk et al., J. Virol., 68, 766, 1994) and a FLAG tag (Hopp et al., Biotechnology 6,, 1204-1210, 1988). The expression and detection of the ChM1L polypeptide fused to these affinity tags can be performed as described in Examples 8 and 9, and it is also possible to purify the ChM1L polypeptide using these tags.

The method of producing the polypeptide encoded by the ChM1L of the present invention is outlined as follows, though more detailed explanations thereof will be made hereinafter in Example 8.

The human and mouse ChM1L gene of the present invention and a gene encoding the ChM1L protein in which a His tag is fused at the C-terminal were cloned into pcDNA3.1(+) vector (Example 4), which was then transfected into COS7 cells. About 48 hours later, the culture supernatant and the cellular components were harvested and were subjected to a Western blot method in order to detect a ChM1L recombinant protein. However, in any of the culture supernatant and the cellular components no expression of ChM1L protein was detected.

Therefore, conditions for detecting the expression of ChM1L recombinant proteins were investigated, and it was found that the use of pCAGGS as the expression vector enables the detection of expression of said polypeptide in COS7 cells. The human and mouse ChM1L gene of the present invention and a gene encoding the ChM1L protein in which a His tag is fused at the C-terminal were cloned into pCAGGS vector (Example 4), which was transfected into COS7 cells. About 48 hours later, the culture supernatant and the cellular components were harvested and were subjected to a Western blot method in order to

detect ChM1L recombinant proteins. No expression of ChM1L recombinant proteins was confirmed in the culture supernatant, whereas in the cellular components two bands were detected at around 40 kDa.

Thus, it was revealed that the ChM1L protein is a membrane-bound protein. On the other hand, it has been confirmed that when ChM-I is expressed in COS7 cells, it is secreted as a soluble protein in the culture supernatant (Hiraki et al., J. Biol. Chem., 272, 32419-32426, 1997). Thus the analysis with COS7 cells revealed that ChM1L and ChM-I are proteins having different structures. That is, it was shown that ChM1L is a cell membrane-bound protein, while ChM-I is a secretary protein, and that the processing mechanisms of these molecules are different. Among the two bands for the ChM1L protein, the band at the high molecular weight was found to be a form modified by a N-linked sugar chain in the Example 10 described below (Figure 6).

The ChM1L protein thus expressed can affinity purified using a ChM1L-specific antibody or an antibody against the tag (His tag) in which 6 residues of histidine are fused, a nickel column and the like.

The polypeptide encoded by the ChM1L gene of the present invention may be any of a membrane-bound polypeptide and a soluble polypeptide having no property of binding to the cell membrane. For example, there may be cases in which after the polypeptide is expressed as a membrane-bound polypeptide on the cell membrane, it is cleaved to become a soluble polypeptide. Though the ChM1L protein was detected as a membrane-bound protein in the expression in COS7 cells (Example 8), it may undergo processing thereby to be a soluble protein when the host cell or the culture condition is different. Furthermore, the soluble polypeptide that lacks the transmembrane domain can be expressed by fusing a heterologous signal peptide to the N-terminal.

More specifically, the method of expressing the

soluble ChM1L protein is outlined as follows, though more detailed explanations thereof will be made hereinafter in Example 9.

A vector was constructed that has integrated, into pCAGGS vector, a nucleotide sequence encoding a protein in which the signal sequence of preprotrypsin, a FLAG tag, the C-terminal end of the extracellular region of ChM1L were fused from the N-terminal end (Example 5). The ChM1L protein that was expressed using this vector was secreted into the culture liquid as a soluble protein after the signal sequence of preprotrypsin was cleaved (Example 9, Figure 5).

The soluble ChM1L polypeptide thus secreted into the culture liquid can be purified using anti-ChM1L antibody or anti-FLAG antibody (Sigma) because a FLAG tag is fused thereto. It is also possible to remove the FLAG tag by cleaving the FLAG fusion protein with enterokinase.

More specifically, the method of purifying the soluble ChM1L protein is outlined as follows though more detailed explanations thereof will be made hereinafter in Example 13.

Using a Lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pSF-shChM1L was transfected into COS7 cells, and 48 hours later the culture supernatant was harvested. From this culture supernatant, a soluble ChM1L protein was purified by affinity chromatography using anti-FLAG M2 affinity gel (Sigma) (Figure 8).

The ChM1L polypeptide of the present invention can be used as a polypeptide-purifying reagent. Said polypeptide bound to a solid support is very useful for the purification of polypeptides that can bind to said peptide by affinity chromatography. As the polypeptide that can bind to the ChM1L polypeptide, there may be illustrated soluble polypeptides, membrane-bound polypeptides, antibodies and the like. The soluble ChM1L polypeptide may be readily used for the addition into the

cell culture liquid in vitro, or intravenous administration in vivo.

In order to search the activity of the ChM1L polypeptide of the present invention, human umbilical vein endothelial cells (HUVECs) were used to analyze the presence of a angiogenesis-inhibiting activity. More specifically, the method is outlined as follows though more detailed explanations thereof will be made hereinafter in Example 14. When HUVECs are cultured on a plate coated with Matrigel (Becton Dickinson), vascular endothelial cells form a tube-like structure (Figure 9). When the ChM1L polypeptide purified by the above-mentioned affinity chromatography is added to the culture liquid, the formation of tube-like structure of HUVECs was inhibited (Figure 9). Therefore, it is clear that ChM1L has a angiogenesis-inhibiting activity, and that the soluble ChM1L polypeptide can be applied as a therapeutic agent for diseases accompanied by angiogenesis such as diabetic retinopathy, cancer, and rheumatoid arthritis.

Using the polypeptide encoded by the ChM1L gene of the present invention, a specific antibody can be generated. An antigen as used herein includes a polypeptide produced in large quantities according to the above genetic engineering method or a chemically synthesized polypeptide, and an antibody obtained may be any of polyclonal antibody or monoclonal antibody, and can be effectively used for the purification, measurement, recognition, and the like of said polypeptide. Hence, polyclonal antibodies and monoclonal antibodies against said polypeptide can be used for treatment or the development of therapeutic methods for diseases that are mediated (directly or indirectly) by said polypeptide, and can also be used as diagnostic reagents for the above diseases.

Antibodies that specifically bind to the polypeptide encoded by the ChM1L gene of the present invention can be

generated as shown in Example 7. That the generated anti-ChM1L polypeptide antibody specifically binds to said polypeptide was confirmed in the result of Western blot shown in Example 8 (Figure 4).

Anti-ChM1L polypeptide antibody may also be used for immunostaining tissue sections as described in Example 11. When a rib cartilage was stained with an anti-ChM1L polypeptide antibody, cells that assume a fibroblast-like flat form occurring in such a way as to surround the cartilaginous tissue were specifically stained (Figure 7). On the other hand, it has been demonstrated that ChM-I is specifically expressed on chondrocytes and immunostaining has also shown that it is accumulated in the chondrocytes and matrices other than the chondrocytes (Hiraki et al., J. Biol. Chem., 272, 32429-32426, 1997). It was therefore revealed that ChM1L and ChM-I are expressed in different cells in the tissue including cartilage, which thereby demonstrated that ChM1L and ChM-I are molecules that have different functions.

The tissue containing the cell group exhibiting a fibroblast-like form that was demonstrated to be expressing the ChM1L protein by immunostaining is conventionally termed as perichondrium (Suda et al., Bone Formation and Bone Absorption and their regulating factors 1, 2, 1995). Though there is no definite definition at present on the tissue perichondrium, it is herein intended to mean a tissue containing cell groups that exhibit a fibroblast-like form.

The cells present in the perichondrium are thought to be a source for chondrocytes that are required for the development of cartilaginous tissues during the process of endochondral bone formation. Hence, the perichondrium is an important tissue that supplies chondrocytes at the time of skeleton formation during the process of development or bone and cartilage injuries in adults. Furthermore, though the cartilaginous tissue is characterized in that there are no blood vessels, nerves,

or lymphatic vessels, the perichondrium is thought to regulate the infiltration of blood vessels, nerves, or lymphatic vessels into the chondrocytes since the perichondrium is present at the interface of cartilaginous tissues and other tissues. Thus, though perichondrium is recognized to be an important tissue, it has no definite definition and detailed study has not been made at present. One reason for this that there are no molecules that are perichondrium-specifically expressed have been elucidated at all.

Accordingly, if the presence of molecules that are specifically expressed in the tissue termed as perichondrium surrounding the cartilaginous tissue is demonstrated, it would provide a very important tool in the study of perichondrium and cartilaginous tissues.

The ChM1L of the present invention is the only molecule that was demonstrated to be perichondrium-specifically expressed, and is thought to regulate the infiltration of blood vessels, nerves, or lymphatic vessels into the cartilaginous tissues.

Hence, the discovery of the ChM1L gene and the result of functional analysis of ChM1L included herein is believed to provide, from now on, a new perspective on the etiology and the development of therapeutic methods for diseases in which perichondrium and other ChM1L-expressing tissues including the cartilaginous tissue are involved.

Thus, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, and agents that promote or reduce the expression of the ChM1L gene are considered to be used as therapeutic agents for diseases in which the above ChM1L-expressing cells are involved.

The above expression analysis of mRNA and the result of immunostaining revealed that the ChM1L gene and the polypeptide encoded thereby of the present invention are expressed in the brain, the eyeball, the skeletal muscle,

the thyroid, the whole rib including cartilage, the kidney, the stomach, the trachea, and cells that assume a fibroblast-like flat form occurring in such a way as to surround the cartilaginous tissue. It suggests, therefore, that the ChM1L gene and the polypeptide encoded thereby of the present invention may be involved in diseases associated with the above tissues that have been confirmed to express them, such as diabetic retinopathy, muscular dystrophy, Basedow's disease, chronic kidney failure, stomach cancer, chronic bronchitis, osteoarthritis and rheumatoid arthritis.

Hence, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, and agents that promote or reduce the expression of the ChM1L gene are considered to be used as therapeutic agents for these diseases.

Examples

The present invention will now be explained more specifically with reference to the following examples. It should be noted, however, that the present invention is not limited to these examples.

Example 1. Analysis of the ChM1L amino acid sequence

The homology of amino acid residues of ChM-I and ChM1L was compared (Figure 1(a)). The amino acid sequence was represented by one alphabetical letter. ChM1L has a homology with ChM-I throughout the molecule, but it was found that ChM1L has a particularly high homology with the C-terminal of ChM-I that is extracellularly secreted following the processing of ChM-I.

The homology of amino acid sequences of human, mouse and rat ChM1L was compared (Figure 1(b)). The ChM1L polypeptide is composed of 317 amino acids in humans, mice, and rats, but the 300 amino acid residues were identical in the three (about 95%).

The degree of hydrophobicity of ChM-I and ChM1L is shown in the figure (Figure 2). In both of ChM-I and ChM1L, a large hydrophobic peak is observed in the N-terminal end. This hydrophobic region is characteristically observed in the cell membrane-bound proteins, and it was demonstrated that both of ChM1L and ChM-I are type II membrane-bound proteins.

Example 2. Cloning of the ChM1L gene

Using the amino acid sequence (Genbank accession number M16441) of human ChM-I, TBLASTN search was performed for the Expressed sequence tag data base (dbEST) in the DNA data bank of Japan (DDBJ). As a result, an EST file, GenbanK accession number AI123839 was detected as a novel gene fragment having a homology with ChM-I.

Using Clontech's Human fetus Marathon-Ready (TM) cDNA, cDNA was amplified by the RACE method according to the instruction attached to the product. Primers were synthesized from the nucleotide sequence obtained from the above dbEST, and ExTaq polymerase (Takara Shuzo) was used according to the according to the instruction attached to the product. Using GeneAmp (TM) PCR System 9700 (PE Applied Biosystems), PCR reaction was carried out for 30 cycles with each cycle comprising 96°C for 30 seconds, 60°C for 30 seconds, and 72°C for one minute, and finally incubated at 72°C for 6 minutes to obtain a PCR reaction mixture. One tenth of the reaction mixture was added, and the second PCR was performed in the same condition.

The PCR product obtained was subjected to electrophoresis on a 1% agarose gel containing ethidium bromide and then the gel was observed under UV irradiation to examine DNA bands. The amplified fragments were excised from the gel, and were purified using QIAquick Gel Extraction Kit (QIAGEN) according to the instruction attached to the product.

The nucleotide sequence of the purified fragment was

determined using a DNA sequencer (ABI PRISM (TM) 310 Genetic Analyzer) of PE Applied Biosystems and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit.

The nucleotide sequence of human ChM1L cDNA is shown in SEQ ID NO: 1 and its amino acid sequence is shown in SEQ ID NO: 2.

Since the amino acid sequence encoded by the human ChM1L gene represented by SEQ ID NO: 1 has a homology with human ChM-I, the gene was decided to be termed as the ChM1L gene (ChM-I like gene).

The coding sequence (CDS) of Human ChM1L cDNA was amplified by PCR, electrophoresed on agarose, and then was purified, which was then cloned using pCR-Script (TM) Amp cloning kit (Stratagene) according to the instruction attached to the product. The sequence of the primers used in PCR are shown in SEQ ID NO: 7 (forward primer) and SEQ ID NO: 8 (reverse primer). The ChM1L gene sequence that has been integrated into the vector was determined using ABI PRISM (TM) 310 Genetic Analyzer of PE Applied Biosystems and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit.

Using the amino acid sequence (SEQ ID NO: 2) of human ChM1L, TBLASTN search was carried out as described in the above human case. As a result, as a gene fragment that encodes mouse ChM1L, EST file, Genbank accession number AV009191 was detected, and as a gene fragment that encodes rat ChM1L, EST file, Genbank accession number AI112003 was detected. Using Mouse 11-day Embryo Marathon-Ready (TM) cDNA and Rat Skeletal muscle Marathon-Ready (TM) cDNA by Clontech, sequences of mouse and rat ChM1L genes were determined by the RACE method as described in the isolation of the human ChM1L gene.

The nucleotide sequence of mouse ChM1L cDNA is shown in SEQ ID NO: 3 and the amino acid sequence is shown in SEQ ID NO: 4. The nucleotide sequence of rat ChM1L cDNA is shown in SEQ ID NO: 5 and the amino acid sequence is

shown in SEQ ID NO: 6.

The coding sequences (CDS) of mouse and rat ChM1L cDNA were amplified by PCR, and were purified after agarose electrophoresis, which were then cloned using pCR-Script (TM) Amp cloning kit (Stratagene) according to the instruction attached to the product. The sequences of the primers used in PCR of the mouse gene are shown in SEQ ID NO: 9 (forward primer) and SEQ ID NO: 10 (reverse primer). The sequences of the primers used in PCR of the rat gene are shown in SEQ ID NO: 11 (forward primer) and SEQ ID NO: 12 (reverse primer). The sequence of the ChM1L gene that was integrated into the vector was determined using ABI PRISM (TM) 310 Genetic Analyzer of PE Applied Biosystems and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit.

The names of human, mouse and rat ChM1L genes constructed in this Example are abbreviated to:

the vector containing the human ChM1L gene: pCR-hChM1L

the vector containing the mouse ChM1L gene: pCR-mChM1L

the vector containing the rat ChM1L gene: pCR-rChM1L

Example 3. Construction of vectors containing genes encoding human and mouse ChM1L proteins in which 6 residues of histidine are fused to the C-terminal

The coding sequences (CDS) of human and mouse ChM1L cDNA were amplified by PCR, and were purified after agarose electrophoresis, which were then cloned using pCR-Script SK(+) vector that has been improved so that 6 histidine residues (His tag) may be fused to the C-terminal and pCR-Script (TM) Amp cloning kit (Stratagene) according to the instruction attached to the product. The sequence of the primers used in PCR of the human gene are shown in SEQ ID NO: 7 (forward primer) and SEQ ID NO: 13 (reverse primer). The sequence of the primers used in PCR of the mouse gene are shown in SEQ ID NO: 9 (forward primer) and SEQ ID NO: 14 (reverse primer). That a

nucleotide sequence encoding a protein in which His tags are fused to the C-terminal of ChM1L was determined using ABI PRISM (TM) 310 Genetic Analyzer (PE Applied Biosystems) and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit according to the instruction attached to the product. The amino acid sequences of human and mouse ChM1L in which His tags were fused to the C-terminal are shown in SEQ ID NO: 17 and 18, and the nucleotide sequence encoding them are shown in SEQ ID NO: 15 and 16.

The genes encoding the ChM1L protein constructed in this Example in which a His tag was fused are abbreviated to:

the vector containing a gene encoding the protein in which human ChM1L and His tags were fused : pCR-hChM1LHis

the vector containing a gene encoding the protein in which mouse ChM1L and His tags were fused : pCR-mChM1LHis

Example 4. Construction of expression vectors

In order to express the ChM1L gene in a mammalian cell, CDSs were excised from the above pCR-hChM1L, pCR-mChM1L, pCR-hChM1LHis, and pCR-mChM1LHis with restriction enzymes EcoRI and NotI, were electrophoresed on agarose, and then the desired bands were purified, which were ligated to pcDNA3.1(+) (Invitrogen) and pCAGGS (Gene, 108, 193-200, 1991) using Ligation high (Toyobo) according to the instruction attached to the product. The solutions after the ligation reaction were subjected to transformation using E. coli JM109 competent cells (Takara Shuzo) according to the instruction attached to the product. After purifying the plasmids, the integration of the desired gene was confirmed by restriction enzyme reactions and agarose electrophoresis.

The vectors constructed in this Example are abbreviated to:

pcDNA3.1(+) vectors containing the hChM1L, mChM1L, hChM1LHis and mChM1LHis: pcDNA-hChM1L, pcDNA-mChM1L, pcDNA-hChM1LHis, and pcDNA-mChM1LHis

pCAGGS vectors containing the hChM1L, mChM1L, hChM1LHis and mChM1LHis: pCAGGS-hChM1L, pCAGGS-mChM1L, pCAGGS-hChM1LHis, and pCAGGS-mChM1LHis

Example 5. Construction of vectors that express human soluble ChM1L protein to which a FLAG tag is fused

The FLAG tag (Sigma) as used herein is a hydrophilic marker peptide comprising eight amino acids (Asp Tyr Lys Asp Asp Asp Asp Lys), and the last five amino acids (Asp Asp Asp Asp Lys) is a recognition sequence for enterokinase. The vectors constructed in this Example can express a protein in which the signal sequence of preprotrypsin, a FLAG tag, the C-terminal end of the extracellular region of ChM1L were fused from the N-terminal end. The protein that was expressed using this vector is secreted into the culture liquid as a soluble protein after the signal sequence of preprotrypsin is cleaved, as explained in detail hereinafter in Example 9. Since a FLAG tag is fused to the protein expressed with this vector, the protein can be purified using anti-FLAG antibody (Sigma) and by cleaving the fusion protein with enterokinase, the FLAG tag can also be removed.

A vector was constructed in which a nucleotide sequence (SEQ ID NO: 19, contained in pFLAG-CMV-1 vector manufactured by Sigma) encoding the signal sequence of preprotrypsin and a FLAG tag (SEQ ID NO: 20) from the N-terminal was integrated into the pCAGGS vector (hereinafter referred to as pSF vector). A nucleotide sequence (nucleotide sequence No. 684 to 1020 of SEQ ID NO: 1) encoding the amino acids No. 212 to 317 of human ChM1L represented by SEQ ID NO: 2 and the translation termination codon was amplified by the PCR method, and the amplified product was integrated into the 3'-end of the nucleotide sequence encoding the FLAG tag of the pSF vector. The sequences of primers used for PCR are shown in SEQ ID NO: 21 (forward primer) and SEQ ID NO: 8 (reverse primer). The integration of the sequence of interest into the constructed vector was confirmed using

a ABI PRISM (TM) 310 Genetic Analyzer (PE Applied Biosystems) and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit according to the instruction attached to the product. The nucleotide sequence of this Example integrated into the vector is shown in SEQ ID NO: 22, and the amino acid sequence encoded thereby is shown in SEQ ID NO: 23. The vector constructed in this Example will be abbreviated to pSF-shChM1L.

Example 6. Expression analysis of ChM1L mRNA

Expression analysis of ChM1L mRNA in various tissues of an adult (10-week old): Figure 3(a)

A 10-week old C57BL/6 mouse was dissected and each tissue was extracted, which was immediately frozen in liquid nitrogen. The frozen tissue was ground into small pieces, and using IOSGEN (Nippon Gene) according to the instruction attached to the product the total RNA of each tissue was obtained. With one μg of total RNA of each tissue as template, 20 μl of cDNA was synthesized using Superscript II preamplification kit (GIBCO BRL) according to the instruction attached to the product. In RT-PCR, the total liquid volume of the reaction system was set at 50 μl, and for each tissue 0.5 μl of cDNA, 0.25 μl of ExTaq polymerase (Takara Shuzo) were used, to which the forward primer (SEQ ID NO: 9) and the reverse primer (SEQ ID NO: 10) were added to a concentration of 0.2 μm. Using GeneAmp (TM) PCR System 9700 (PE Applied Biosystems), PCR amplification was performed for 30 cycles with each cycle comprising 96°C for 30 seconds, 60°C for 30 seconds, and 72°C for one minute. The reaction mixture obtained was subjected to electrophoresis on a 1% agarose gel containing ethidium bromide and then the gel was observed under UV irradiation to examine the expression of ChM1L mRNA in each tissue.

As shown in Figure 3(a), the expression of ChM1L

mRNA in each tissue of an adult mouse was observed in the brain, the eyeball, the skeletal muscle, the whole rib, and the thyroid. The expression of ChM-I in mice has been confirmed in the eyeball, the thymus, the cartilage, and the whole rib. It is therefore clear that ChM1L and ChM-I are expressed in different tissues in the living body, suggesting that their physiological functions are different.

Expression analysis of ChM1L mRNA in various tissues of a fetus (day 17 of gestation): Figure 3(b)

A fetus of C57BL/6 mouse on day 17 of gestation was removed by Caesarean section. Each tissue was taken out, and was immediately frozen in liquid nitrogen. The extraction of total RNA from the frozen tissue, cDNA synthesis, and RT-PCR were performed as described in the above <Expression analysis of ChM1L mRNA in various tissues of an adult mouse>.

As shown in Figure 3(b), the expression of ChM1L mRNA in each tissue of a fetus mouse was observed in the eyeball, the kidney, the stomach, the whole rib, and the trachea. In the fetus, expression in the kidney and the stomach was observed, in which no expression was observed in the adult mouse. It is therefore likely that ChM1L is involved in the development and morphogenesis of these organs, and is also considered to be involved in the repair and regeneration of organs. It was also revealed that ChM1L mRNA is expressed in the trachea.

Expression analysis of ChM1L mRNA during the developmental stage of a fetus: Figure 3(c)

A fetus of C57BL/6 mouse on each day from day 10 of gestation to childbirth was removed by Caesarean section. Each the whole fetuses was frozen in liquid nitrogen. The extraction of total RNA from the frozen fetus, cDNA synthesis, and the implementation of RT-PCR were performed as described in the above <Expression analysis of ChM1L mRNA in various tissues of an adult mouse>.

The analysis of ChM-I mRNA was carried out using a

fusion protein (SEQ ID NO: 23) and a reverse primer (SEQ ID NO: 24) under the same condition as above.

As shown in Figure 3(c), the expression of ChM1L mRNA during the developmental stage of the fetus is very weak on day 10 of gestation and is increased in expression on days 11 to 13. On the other hand, though the expression of ChM-I was also increased as for ChM1L, it exhibited an evidently stronger expression than ChM1L on days 10 and 11 of gestation. It is therefore clear that the expression of ChM1L lags behind ChM-I during the developmental stage of the fetus, and that these molecules have different functions in the fetus development.

Example 7. Generation of anti-ChM1L peptide polyclonal antibody

A peptide having cysteine at the C-terminal of the sequence from 245 to 252 residues shown in SEQ ID NO: 2 of human ChM1L was chemically synthesized. To this synthetic peptide, MBS/KLH (m-maleimidobenzoyl-N-hydroxysuccinimide ester/keyhole limpet hemocyanin, Boehringer Mannheim) was coupled. After the complex was dissolved in physiological saline, an equal amount of Freund's complete adjuvant (FCA) was added, which was sonicated to prepare an emulsion. This emulsion was subcutaneously given to a rabbit as the initial immunization. Four weeks after the initial immunization, a booster immunization was carried out using Freund's incomplete adjuvant (FIA) to the femoral muscle, and thereafter immunization by subcutaneous administration was carried out for four times at an interval of about two weeks or four weeks. During the booster immunization, blood was partially taken from the auricle, and after the final immunization the entire blood was taken and serum was separated. By affinity purification using a peptide column, an anti-ChM1L peptide polyclonal antibody was obtained.

Example 8. Analysis of human and mouse ChM1L recombinant protein by Western blotting: Figure 4

Using the lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pCAGGS, pCAGGS-hChM1L and pCAGGS-mChM1L (Figure 4(a) and (c)), or pCAGGS, pCAGGS-hChM1LHis and pCAGGS-mChM1LHis (Figure 4(b) and (d)) were transfected into COS7 cells. About 48 hours after the transfection, the culture supernatant and the cellular components were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 12.5% gel, and then transferred to a nitrocellulose membrane. A primary antibody reaction and a secondary antibody reaction were carried out, and then subjected to a color developing reaction using the ECLplus reagent (Amersham Pharmacia Biotech) according to the instruction attached to the product. In the Western blot in which pCAGGS, pCAGGS-hChM1L and pCAGGS-mChM1L were transfected, anti-ChM1L polyclonal antibody described in the above Example was used as the primary antibody and horseradish peroxidase (HRP)-labelled anti-rabbit IgG antibody (DAKO) was used as the secondary antibody, and in the Western blot in which pCAGGS, pCAGGS-hChM1LHis and pCAGGS-mChM1LHis were transfected, anti-His tag antibody (Invitrogen) was used as the primary antibody and HRP-labelled anti-mouse IgG antibody (Amersham Pharmacia Biotech) was used as the secondary antibody.

SDS-PAGE was carried out for the same samples as in Western blot, and the results of staining with Coomassie brilliant blue (CBB) are shown in Figure 4(a) and (b).

As a result of Western blot, no ChM1L band was confirmed in any of the culture supernatants. In cellular components, as shown in Figure 4(b) and (d), recombinant ChM1L protein was detected as two bands at around 40 kDa whether anti-ChM1L peptide antibody or anti-His tag antibody was used. As will be described in detail in the Examples below, the band at the high

molecular weight was confirmed to be a form in which a N-linked glycosylation.

Example 9. Analysis of soluble human ChM1L recombinant protein by a Western blot method: Figure 5

Using the lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pCAGGS and pSF-shChM1L were transfected into COS7 cells. After the culture supernatants were subjected to SDS-PAGE on a 12.5% gel, they were transferred to a nitrocellulose membrane. Anti-FLAG M2 antibody (Sigma) was used as the primary antibody and HRP-labelled anti-mouse IgG antibody (DAKO) was used as the secondary antibody, and the ECLplus reagent (Amersham Pharmacia Biotech) was used according to the instruction attached to the product to perform color development reaction.

As shown in Figure 5, soluble human ChM1L protein was detected as a single band at around 17-18 kDa.

Example 10. Deglycosylation analysis of ChM1L recombinant protein

Using the lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pCAGGS-mChM1LHis was transfected into COS7 cells. After PBS saline containing 2% SDS was added to a dish, cells were harvested by a scraper, and the suspension was heated at 95°C for 60 minutes. The supernatant was treated with SDS-OUT (TM) SDS Precipitation kit (Pierce) to remove SDS. Using the protein solution thus obtained, a deglycosylation was carried out using the Enzymatic Deglycosylation Kit (BIO RAD) according to the instruction attached to the product to treat the above protein solution with NANase II, O-glycosidase DS and PNGase F. After the reaction mixture was subjected to SDS-PAGE on a 12.5% gel, it was transferred to a nitrocellulose membrane. Anti-His tag antibody (Invitrogen) was used as the primary antibody and HRP-labelled anti-mouse IgG antibody (Amersham Pharmacia Biotech) was used as the secondary antibody, and the

ECLplus reagent (Amersham Pharmacia Biotech) was used according to the instruction attached to the product to perform color development reaction.

As shown in Figure 6, the band of ChM1L protein at the high molecular weight disappeared only when treated with pNGase F (lanes 2 and 5). It was therefore demonstrated that the ChM1L protein has been modified with a N-linked sugar chain.

Example 11. Analysis of ChM1L protein at cartilago costalis by immunostaining

An about 10-week old C57BL/6 mouse was dissected to remove the whole rib, which was fixed in a 10 mM phosphate buffer (pH 7.4) (PBS) containing 4% paraformaldehyde, embedded in paraffin, and then sections were prepared. Each step of immunostaining was carried out using Histfine SAB-PO(R) kit (Nichirei) according to the instruction attached to the product, of which outline is as follows: After deparaffinization, endogenous peroxidase was digested with a 3% hydrogen peroxide. After washing with PBS followed by blocking with 10% normal goat serum, the above-mentioned anti-ChM1L peptide antibody at a dilution of 1/160 was added and incubated overnight at 4°C. As a negative control, rabbit IgG was used. After biotin-labelled anti-rabbit IgG antibody and peroxidase-labelled streptoavidin were allowed to react, 3,3-diaminobendizine/4HCl was added to perform a color development reaction. The nucleus was stained with haematoxylin, enclosed, and then observed.

As shown in Figure 7, ChM1L protein is expressed in cells that assume a fibroblast-like flat form occurring in such a way as to surround the cartilaginous tissue. On the other hand, there were no expressions observed in the cartilage cell in which the expression of ChM-I has been reported.

Example 12. Chromosome mapping of the human ChM1L gene

Using the gene sequence (SEQ ID NO: 1) of human ChM1L, BLASTN search was performed for the entire DDBJ

data from the DNA data bank of Japan (DDBJ). As a result, Genbank accession number AL035608 was detected as the genome sequence of the ChM1L gene. AL035608 is a sequence mapped on chromosome X. It is therefore clear that the human ChM1L gene is present on chromosome X.

Example 13. Purification of a soluble human ChM1L recombinant protein

Using a Lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pSF-shChM1L was transfected into COS7 cells, and 48 hours later the culture supernatant was harvested. Using anti-FLAG M2 affinity gel (Sigma), an affinity column was prepared, and the culture supernatant was applied to the column. After washing the column three times in 25 mM Tris-HCl, 150 mM NaCl (pH 7.4), it was eluted with 0.1 M glycine-HCl (pH 3.5), and the eluent was neutralized with a 1/20 volume of 1M Tris-HCl (pH 9.5).

The culture supernatant and the eluent were subjected to SDA-PAGE and then were stained with Coomassie brilliant blue (CBB), the result of which is shown in Figure 8. Though there are a variety of proteins in the culture supernatant (Figure 8, lane 1), soluble human ChM1L protein was confirmed as an about 20 kDa band in the eluent. This revealed that soluble human ChM1L protein was concentrated and purified by the above procedure (Figure 8, lane 2).

Example 14. Study on the effect of inhibiting angiogenesis using human umbilical vein endothelial cells

Human umbilical vein endothelial cells (HUVECs, Clonetics) were cultured in a exclusive medium (EGM (TM)-2 Bullet Kit(TM), Clonetics) for endothelial cells. To a 12-well plate, Growth factor reduced Matrigel (Becton Dickinson) was added to 600 µl/well, which was then incubated at 37°C for 30 minutes. Using a heparin-free exclusive medium for endothelial cells diluted 1/8 in the essential medium (EBM (TM)-2, Clonetics) for endothelial cells, a cell suspension containing 5 x 10^4 cells/ml of

HUVECs were prepared.

Each test substance solution was prepared as a solution in which a 1/20 volume of 1M Tris-HCl (pH 9.5) was added to 0.1M glycine-HCl (pH 3.5), and 200 µl/well of it was treated. The above buffer and bovine serum albumin (BSA) at 20 µg/well as the negative control, platelet factor 4 (PF-4, CHEMICON) at 1 and 10 µg/well as the positive control, and the eluted fractions of Example 13 at 10 and 20 µg/well as the soluble human ChM1L recombinant protein were treated. Two ml of the cell suspension (1 x 10^5 cells) and 200 µl of the test substance solution were mixed, and seeded into a 12-well plate coated with Growth factor reduced Matrigel. Nine hours later, the formation of tube-like structures was examined and were a photograph was taken. The result is shown in Figure 9. In the negative control, HUVECs formed tube-like structures (Figure 9(a) and (b)), but when ChM1L at 20 µg/well (Figure 9(d)) was treated the formation of tube-like structures was inhibited as compared to the negative control.

It was therefore revealed that ChM1L has an effect of inhibiting angiogenesis and thus the soluble ChM1L polypeptide can be used as a therapeutic agent for disease accompanied by angiogenesis such as diabetic retinopathy, cancer, and rheumatoid arthritis.

What is claimed is:

1. A human gene encoding a polypeptide that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2.

2. A mouse gene encoding a polypeptide that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 4.

3. A rat gene encoding a polypeptide that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 6.

4. The human gene according to claim 1 having the nucleotide sequence as set forth in SEQ ID NO: 1.

5. The mouse gene according to claim 2 having the nucleotide sequence as set forth in SEQ ID NO: 3.

6. The rat gene according to claim 3 having the nucleotide sequence as set forth in SEQ ID NO: 5.

7. A polypeptide encoded by a human gene that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2.

8. A polypeptide encoded by a mouse gene that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 4.

9. A polypeptide encoded by a rat gene that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 6.

10. An oligonucleotide probe that hybridizes to at least part of the gene according to any one of claims 1 to 6.

11. A recombinant DNA comprising the gene according to any one of claims 1 to 6.

12. A transformant transformed with the recombinant DNA according to claim 11.

13. A method of producing a polypeptide encoded by a human, mouse and rat gene which method comprises culturing the transformant according to claim 12 and harvesting said polypeptide from the culture.

14. A monoclonal antibody that specifically reacts

with the polypeptide according to any one of claims 7 to 9.

15. A polyclonal antibody that specifically reacts with the polypeptide according to any one of claims 7 to 9.

16. A hybridoma that produces the monoclonal antibody according to claim 14 that is obtained by fusing an antibody-producing cell immunized with the polypeptide according to any one of claims 7 to 9 to a myeloma cell.

17. A reagent for detecting a gene said reagent comprising the above oligonucleotide probe according to claim 10.

18. A diagnostic kit that comprises the polypeptide according to any one of claims 7 to 9 and the above monoclonal antibody according to claim 14 and/or the polyclonal antibody according to claim 15.

19. A pharmaceutical composition comprising a polypeptide according to any one of claims 7 to 9.

20. A pharmaceutical composition comprising the monoclonal antibody according to claim 14 or the polyclonal antibody according to claim 15.

21. A pharmaceutical composition comprising an antisense oligonucleotide that specifically hybridizes to part of the gene according to claims 1 to 6.

22. A pharmaceutical composition comprising a nucleic acid that can be used in gene therapy said composition comprising at least part of the gene according to claims 1 to 6.

23. The human gene according to claim 1 or 4 characterized in that it is present on chromosome X.

24. The polypeptide according to claims 7 to 9 wherein said polypeptide is a membrane-bound form.

25. A gene encoding the membrane-bound polypeptide according to claim 24.

26. The polypeptide according to claims 7 to 9 having an effect of inhibiting angiogenesis.

27. The gene encoding the polypeptide according to

claim 26 said polypeptide having an effect of inhibiting angiogenesis.

ABSTRACT

A polypeptide having the amino acid sequence as set forth in SEQ ID NO: 2, 4, or 6, a DNA encoding the same, and an antibody against said polypeptide, and the use thereof. The above amino acid sequence has a homology with chondromodulin-I that has an effect of controlling the growth and differentiation of chondrocytes and inhibiting angiogenesis.

Fig.1A

hChM-I : human ChM-I
hChM1L : human ChM1L

```
hChM-I      MTENSDKVPIALVGPDDVEFCSPPAYATLTVKPSSPARLLKVGAVVLISGAVLLLFGAIG
hChM1L      ---------MAKNPPENCEDCHILNAEAFKSKK--ICKSLKICGLVFGILALTLIVLFWG
                     *   *   * *          *       **    *    * *     *

hChM-I      AFYFWKGSDSHIYNVHYTMSINGKLQDGSMEIDAGNNLETFKMGSGAEEAIAVNDFQNGI
hChM1L      SKHFWPEVPKKAYDMEHTFYSNGEKKKIYMEIDPVTRTEIFRSGNGTDETLEVHDFKNGY
               **       *    *   **      ****     * *  * *  *   * ** **

hChM-I      TGIRFAGGEKCYIKAQVKARIPEVGAVTKQSISSKLEGKIMPVKYEENSLIWVAVDQPVK
hChM1L      TGIYFVGLQKCFIKTQIKV-IPEFSEPEEEID----ENEEITTTFFEQSVIWVPAEKPIE
            *** * *  ** ** * *  ***             *         * * ***    *

hChM-I      DNSFLS-SKVLELCGDLPIFWLKPTYP--KEIQRERREVVRKIVPTTTKRPHSGPRSNPG
hChM1L      NRDFLKNSKILEICDNVTMYWINPTLISVSELQDFEEEGEDLHFPANEKKGIEQNEQWVV
               **  ** ** *      *  **     * *    *      *   *

hChM-I      AGRLNNETRPSVQEDSQAFNPDNPYHQQEGESMTFDPRLDHEGICCIECRRSYTHCQKIC
hChM1L      PQVKVEKTRHAR----QASEEELPINDYTENGIEFDPMLDERGYCCIYCRRGNRYCRRVC
                    **       **     *          *** **  * *** ***    *   *

hChM-I      EPLGGYYPWPYNYQGCRSACRVIMPCSWWVARILGMV
hChM1L      EPLLGYYPYPYCYQGGRVICRVIMPCNWWVARMLGRV
            *** **** ** *** *  ******* ***** ** *
```

Fig.1B

hChM1L : human ChM1L
mChM1L : mouse ChM1L
rChM1L : rat ChM1L

```
mChM1L      MAKNPPENCEGCHILNAEALKSKKICKSLKICGLVFGILALTLIVLFWGSKHFWPEVSKK
rChM1L      MAKNPPENCEGCHILNAEALKSKKIRKSLKICGLVFGILALTLIVLFWGSKHFWPEVSKK
hChM1L      MAKNPPENCEDCHILNAEAFKSKKICKSLKICGLVFGILALTLIVLFWGSKHFWPEVPKK
            ********** ******** ***** ******************************** **

mChM1L      TYDMEHTFYSNGEKKKIYMEIDPITRTEIFRSGNGTDETLEVHDFKNGYTGIYFVGLQKC
rChM1L      TYGMEHTFYSNGEKKKISMEIDPITRTEIFRSGNGTDETLEVHDFKNGYTGIYFVGLQKC
hChM1L      AYDMEHTFYSNGEKKKIYMEIDPVTRTEIFRSGNGTDETLEVHDFKNGYTGIYFVGLQKC
             * ************** ***** ***********************************

mChM1L      FIKTQIKVIPEFSEPEEEIDENEEITTTFFEQSVIWVPAEKPIENRDFLKNSKILEICDN
rChM1L      FIKTQIKVIPEFSEPEEEIDENEEITTTFFEQSVIWVPAEKPIENRDFLKNSKILEICDN
hChM1L      FIKTQIKVIPEFSEPEEEIDENEEITTTFFEQSVIWVPAEKPIENRDFLKNSKILEICDN
            ************************************************************

mChM1L      VTMYWINPTLIAVSELQDFEEDGEDLHFPTSEKKGIDQNEQWVVPQVKVEKTRHTRQASE
rChM1L      VTMYWINPTLIAVSELQDFEEDGEDLHFPTSEKKGIDQNEQWVVPQVKVEKTRRTRQASE
hChM1L      VTMYWINPTLISVSELQDFEEEGEDLHFPANEKKGIEQNEQWVVPQVKVEKTRHARQASE
            *********** ********** *******  ***** ***************  *****

mChM1L      EDLPINDYTENGIEFDPMLDERGYCCIYCRRGNRYCRRVCEPLLGYYPYPYCYQGGRVIC
rChM1L      EDLPVNDYTENGIEFDPMLDERGYCCIYCRRGNRYCRRVCEPLLGYYPYPYCYQGGRVIC
hChM1L      EELPINDYTENGIEFDPMLDERGYCCIYCRRGNRYCRRVCEPLLGYYPYPYCYQGGRVIC
            * ** ************************************************************

mChM1L      RVIMPCNWWVARMLGRV
rChM1L      RVIMPCNWWVARMLGRV
hChM1L      RVIMPCNWWVARMLGRV
            *****************
```

Fig. 2

(a) hChM-I : human ChM-I
(b) hChM1L : human ChM1L
(c) mChM1L : mouse ChM1L









Fig. 3

(a) EXPRESSION AT VARIOUS TISSUES OF ADULT (10-WEEK OLD) 1. BRAIN, 2. EYEBALL, 3. LUNG, 4. THYMUS, 5. HEART, 6. LIVER, 7. KIDNEY, 8. STOMACH, 9. SPLEEN, 10. SKELETAL MUSCLE, 11. WHOLE RIB, 12. FAT, 13. ADRENAL, 14. PITUITARY, 15. THYROID, 16. INTESTINE

(b) EXPRESSION AT VARIOUS TISSUES OF FETUS (DAY 17 OF GESTATION) 1. BRAIN, 2. EYEBALL, 3. LUNG, 4. THYMUS, 5. HEART, 6. LIVER, 7. KIDNEY, 8. SPLEEN, 9. STOMACH, 10. INTESTINE, 11. WHOLE RIB, 12. TRACHEA, 13. PANCREAS

(c) EXPRESSION DURING THE DEVELOPMENTAL STAGE OF FETUS 1. DAY 10 OF GESTATION, 2. DAY 11 OF GESTATION, 3. DAY 12 OF GESTATION, 4. DAY 13 OF GESTATION, 5. DAY 14 OF GESTATION, 6. DAY 15 OF GESTATION, 7. DAY 16 OF GESTATION, 8. DAY 17 OF GESTATION, 9. DAY 18 OF GESTATION, 10. DAY OF CHILDBIRTH

(a)



(b)



(c)



Fig. 4

(a) SDS-PAGE: 1. MOCK, 2. HUMAN ChM1L, 3. MOUSE ChM1L
(b) SDS-PAGE: 1. MOCK, 2. HUMAN ChM1L(His), 3. MOUSE ChM1L(His)
(c) WESTERN BLOT (DETECTION WITH ANTI-PEPTIDE ANTIBODY):
1. MOCK, 2. HUMAN ChM1L, 3. MOUSE ChM1L
(d) WESTERN BLOT (DETECTION WITH ANTI-His TAG ANTIBODY):
1. MOCK, 2. HUMAN ChM1L(His), 3. MOUSE ChM1L(His)



Fig. 5

1. Mock
2. soluble human ChM1L



Fig. 6

1. NON-TREATED, 2. TREATED WITH NANase II + O-GLYCOSIDASE DS + PNGase F, 3. TREATED WITH NANase II, 4. TREATED WITH O-GLYCOSIDASE DS, AND 5. TREATED WITH PNGase F



Fig.7

(a) RABBIT IgG



(b) ANTI-ChM1L PEPTIDE ANTIBODY



Fig. 8



Fig. 9

(a) Buffer control

(b) BSA (20ug/well)



(c) shChM1L (10ug/well)



(d) shChM1L (20ug/well)



(e) PF-4 (1ug/well)



(f) PF-4 (10ug/well)



Declaration and Power of Attorney for Patent Application
特許出願宣言書および委任状

Japanese Language Declaration

日本語宣言書

私は下記発明者として以下の通り宣言します：

As a below named inventor, I hereby declare that:

私の住所、郵送先、および国籍は私の氏名の後に記載された通りです。

My residence, mailing address and citizenship are as stated next to my name.

下記名称の発明に関し請求範囲に記載され特許出願がされている発明内容につき、私が最初、最先かつ唯一の発明者（下記氏名が一つのみの場合）であるか、あるいは最初、最先かつ共同発明者（下記氏名が複数の場合）であると信じます。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A Novel polypeptide and gene encoding the same

下記項目に×印が付いている場合を除き、上記発明の明細書は本書に添付されます。

the specification of which is attached hereto unless the following box is checked:

☐ 上記発明は米国出願番号あるいはPCT国際出願番号（確認番号______）として___年__月__日に出願され、
___年__月__日に補正されました（該当する場合）。

☒ was filed on September 29, 2000 as United States Application Number or PCT International Application Number PCT/JP00/06804 (Conf. No.______) and was amended on ______ (if applicable).

私は特許請求範囲を含み上述の補正で補正された前記明細書の内容を検討し、理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は連邦規則法典第 37 編 1 条 56 項に定義される特許性に肝要な情報について開示義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

Japanese Language Declaration

日本語宣言書

私は米国法典第 35 編 119 条(a)-(d)あるいは 365 条(b)に基づき特許あるいは発明者証書の下記外国出願、または 365 条(a)に基づき米国以外の少なくとも 1 ヶ国を指定した下記 PCT 外国出願についての外国優先権をここに主張するとともに、下記項目に×印を付けることにより優先権を主張する出願以前の出願日を有する特許あるいは発明者証書の外国出願あるいは PCT 外国出願を示します。

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below, and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior foreign application(s) 外国での先行出願			Priority Claimed 優先権の主張	
			Yes 有り	No 無し
11-275947(Pat.Appln.) (Number) (番号)	Japan (Country) (国名)	29 / September / 1999 (Day/Month/Year Filed) (出願年月日)	☒	☐
(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願年月日)	☐	☐

私は米国法典第35編119条(e)に基づき下記の米国仮特許の利益をここに主張します。

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application No.) (出願番号)	(Filing Date) (出願日)
(Application No.) (出願番号)	(Filing Date) (出願日)

私は米国法典第 35 編 120 条に基づき下記米国特許出願、あるいは 365 条(c)に基づき米国を指定する下記 PCT 国際特許出願の利益をここに主張し、本特許出願内特許請求範囲の各項目の内容が米国法典第 35 編 112 条の最初の項に規定される方法により先行米国あるいは PCT 国際特許出願で開示されていない限りにおいて連邦規則法典第 37 編 1 条 56 項に定義される特許性に肝要で、先行特許出願の出願日から本特許出願の国内あるいは PCT の出願日までの間に入手された情報について開示義務があることを認めます。

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: patented, pending, abandoned) (状態: 特許成立済、係属中、放棄済)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: patented, pending, abandoned) (状態: 特許成立済、係属中、放棄済)

私は本宣言書内で私自身の知識に基づいてなされたすべての陳述が真実であり、情報および信ずるところに基づいてなされたすべての陳述が真実であると信じられていることをここに宣言し、さらに故意になされた虚偽の陳述等々は米国法典第 18 編 1001 条に基づき罰金あるいは拘禁または両方による処罰にあたり、またかような故意による虚偽の陳述はそれに基づく特許出願あるいは成立特許の有効性を危うくする可能性があることを認識した上でこれらの陳述をなしたことを宣言します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration

日本語宣言書

委任状：私は下記の米国特許商標局（USPTO）顧客番号のもとに記載される SUGHRUE MION 法律事務所のすべての弁護士を、同顧客番号のもとに記載される個々の弁護士は SUGHRUE MION 法律事務所のみの自由裁量に基づき変更され得ることを認識した上で、本特許出願の手続きおよびそれに関わる特許商標局との業務を遂行する弁護士として指名し、本特許出願に関するすべての通信が同 USPTO 顧客番号のもとに提出された住所宛に送付されることを要請します。

POWER OF ATTORNEY: I hereby appoint all attorneys of SUGHRUE MION, PLLC who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of SUGHRUE MION, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.

23373

PATENT TRADEMARK OFFICE

電話連絡は下記へ：(名前および電話番号)

SUGHRUE MION, PLLC
(202) 293-7060

Direct Telephone Calls to: (name and telephone number)

SUGHRUE MION, PLLC
(202) 293-7060

1-00 Full name of sole or first inventor 唯一あるいは第一の発明者名 Kei Yamana	
Inventor's signature 発明者の署名 Kei Yamana	Date 日付 March 12, 2002
Residence 住所 Hino-shi, Tokyo, Japan JPX	
Citizenship 国籍 Japanese	
Mailing Address 郵送先 c/o TEIJIN LIMITED, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065, Japan	
2-00 Full name of second joint inventor, if any 第二の共同発明者名（該当する場合） Yukimi Nagasawa	
Second inventor's signature 第二発明者の署名 Yukimi Nagasawa	Date 日付 March 12, 2002
Residence 住所 Hino-shi, Tokyo, Japan JPX	
Citizenship 国籍 Japanese	
Mailing Address 郵送先 c/o TEIJIN LIMITED, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065, Japan	

3-00

Full name of third joint inventor, if any
第三の共同発明者名（該当する場合）
Hitoshi Wada

Third inventor's signature
第三発明者の署名
Hitoshi Wada

Date
日付
March 12, 2002

Residence
住所
Hino-shi, Tokyo, Japan JPX

Citizenship
国籍
Japanese

Mailing Address
郵送先
c/o TEIJIN LIMITED, Tokyo Research Center,
3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065, Japan

4-00

Full name of fourth joint inventor, if any
第四の共同発明者名（該当する場合）
Yoshinori Kasahara

Fourth inventor's signature
第四発明者の署名
Yoshinori Kasahara

Date
日付
March 12, 2002

Residence
住所
Hino-shi, Tokyo, Japan JPX

Citizenship
国籍
Japanese

Mailing Address
郵送先
c/o TEIJIN LIMITED, Tokyo Research Center,
3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065, Japan

Full name of fifth joint inventor, if any
第五の共同発明者名（該当する場合）

Fifth inventor's signature
第五発明者の署名

Date
日付

Residence
住所

Citizenship
国籍

Mailing Address
郵送先

Full name of sixth joint inventor, if any
第六の共同発明者名（該当する場合）

Sixth inventor's signature
第六発明者の署名

Date
日付

Residence
住所

Citizenship
国籍

Mailing Address
郵送先

SEQUENCE LISTING

<110> Teijin Limited

<120> A NOVEL POLYPEPTIDE AND GENE ENCODING THE SAME

<130> Q69170

<150> PCT/JP00/06804
<151> 2000-09-29

<150> JP 11-275947
<151> 1999-09-29

<160> 25

<170> PatentIn version 3.1

<210> 1
<211> 1200
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (67)..(1020)
<223>

<400> 1
ctccacctca gcaggtgtct ctcagtcctc tcaaagcaag gaaagagtac tgtgtgctga 60

gagacc atg gca aag aat cct cca gag aat tgt gaa gac tgt cac att 108
Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile
1 5 10

cta aat gca gaa gct ttt aaa tcc aag aaa ata tgt aaa tca ctt aag 156
Leu Asn Ala Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys
15 20 25 30

att tgt gga ctg gtg ttt ggt atc ctg gcc cta act cta att gtc ctg 204
Ile Cys Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu
35 40 45

ttt tgg ggg agc aag cac ttc tgg ccg gag gta ccc aaa aaa gcc tat 252
Phe Trp Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr
50 55 60

gac atg gag cac act ttc tac agc aat gga gag aag aag aag att tac 300
Asp Met Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr
65 70 75

atg gaa att gat cct gtg acc aga act gaa ata ttc aga agc gga aat 348
Met Glu Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn
80 85 90

ggc act gat gaa aca ttg gaa gta cac gac ttt aaa aac gga tac act 396
Gly Thr Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr
95 100 105 110

ggc atc tac ttc gtg ggt ctt caa aaa tgt ttt atc aaa act cag att 444
Gly Ile Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile
115 120 125

aaa gtg att cct gaa ttt tct gaa cca gaa gag gaa ata gat gag aat 492
Lys Val Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn
130 135 140

gaa gaa att acc aca act ttc ttt gaa cag tca gtg att tgg gtc cca 540
Glu Glu Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro
145 150 155

gca gaa aag cct att gaa aac cga gat ttt ctt aaa aat tcc aaa att 588
Ala Glu Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile
160 165 170

ctg gag att tgt gat aac gtg acc atg tat tgg atc aat ccc act cta 636
Leu Glu Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu
175 180 185 190

ata tca gtt tct gag tta caa gac ttt gag gag gag gga gaa gat ctt 684
Ile Ser Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu
195 200 205

cac ttt cct gcc aac gaa aaa aaa ggg att gaa caa aat gaa cag tgg 732
His Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp
210 215 220

gtg gtc cct caa gtg aaa gta gag aag acc cgt cac gcc aga caa gca 780
Val Val Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala
225 230 235

agt gag gaa gaa ctt cca ata aat gac tat act gaa aat gga ata gaa 828
Ser Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu
240 245 250

ttt gat ccc atg ctg gat gag aga ggt tat tgt tgt att tac tgc cgt 876
Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg
255 260 265 270

cga ggc aac cgc tat tgc cgc cgc gtc tgt gaa cct tta cta ggc tac 924
Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr
275 280 285

tac cca tat cca tac tgc tac caa gga gga cga gtc atc tgt cgt gtc 972
Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val
290 295 300

atc atg cct tgt aac tgg tgg gtg gcc cgc atg ctg ggg agg gtc taa 1020
Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
305 310 315

taggaggttt gagctcaaat gcttaaactg ctggcaacat ataataaatg catgctattc 1080

aatgaatttc tgcctatgag gcatctggcc cctggtagcc agctctccag aattacttgt 1140

aggtaattcc tctcttcatg ttctaataaa cttctacatt atcaccaaaa aaaaaaaaaa 1200

<210> 2

<211> 317
<212> PRT
<213> Homo sapiens

<400> 2

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile Leu Asn
1 5 10 15

Ala Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys
20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp
35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr Asp Met
50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu
65 70 75 80

Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr
85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile
100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val
115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu
130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu
145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu
165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ser
180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His Phe
195 200 205

Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val
210 215 220

```
Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu
225                 230                 235                 240

Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp
                245                 250                 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly
            260                 265                 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro
        275                 280                 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met
    290                 295                 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
305                 310                 315


<210>  3
<211>  1180
<212>  DNA
<213>  Mus musculus

<220>
<221>  CDS
<222>  (59)..(1012)
<223>


<400>  3
agcagtagtc ctctcagtcc tctcaaagca gggaaagagc accgtgtgct gggagacc        58

atg gca aag aat cct cca gag aac tgt gag ggc tgt cac att cta aat       106
Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn
1               5                   10                  15

gca gaa gct ctg aaa tct aag aag ata tgt aaa tca ctg aag att tgt       154
Ala Glu Ala Leu Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys
            20                  25                  30

gga cta gtg ttt ggt atc ctg gcc tta act cta att gtc ctg ttt tgg       202
Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp
        35                  40                  45

ggg agc aaa cac ttc tgg ccc gag gta tcc aag aaa acc tat gac atg       250
Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Asp Met
    50                  55                  60

gag cac act ttc tac agc aac ggc gag aag aag aag att tac atg gaa       298
Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu
65                  70                  75                  80
```

att gat ccc ata acc aga aca gaa ata ttc aga agt gga aat ggc act 346
Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr
85 90 95

gat gaa aca ttg gaa gtc cat gac ttt aaa aat gga tac act ggc atc 394
Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile
100 105 110

tac ttt gta ggt ctt caa aaa tgc ttt att aaa act caa atc aaa gtg 442
Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val
115 120 125

att cct gaa ttt tct gaa cca gag gaa gaa ata gat gag aat gaa gaa 490
Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu
130 135 140

att act aca act ttc ttt gaa cag tca gtg att tgg gtt ccc gca gaa 538
Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu
145 150 155 160

aag cct att gaa aac aga gac ttc ctg aaa aat tct aaa att ctg gag 586
Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu
165 170 175

att tgc gat aat gtg acc atg tac tgg atc aat ccc act cta ata gca 634
Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala
180 185 190

gtt tca gaa tta cag gac ttt gag gag gac ggt gaa gat ctt cac ttt 682
Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe
195 200 205

cct acc agt gaa aaa aag ggg att gac cag aat gag caa tgg gtg gtc 730
Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val
210 215 220

ccg caa gtg aag gtg gag aag acc cgc cac acc aga caa gca agc gag 778
Pro Gln Val Lys Val Glu Lys Thr Arg His Thr Arg Gln Ala Ser Glu
225 230 235 240

gaa gac ctt cct ata aat gac tat act gaa aat gga att gaa ttt gac 826
Glu Asp Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp
245 250 255

cca atg ctg gat gag aga ggt tac tgt tgt att tac tgt cgt cga ggc 874
Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly
260 265 270

aac cgt tac tgc cgc cgt gtc tgt gaa cct tta cta ggc tac tac cca 922
Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro
275 280 285

tac ccc tac tgc tac caa gga ggt cga gtc atc tgt cgt gtc atc atg 970
Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met
290 295 300

cct tgc aac tgg tgg gtg gcc cgc atg ctt ggg aga gtc taa 1012
Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
305 310 315

taggaagatt gagttcaaac gcttaacctt ctgttagcca atatataatt aatgcatgct 1072

actccatgaa tttctgccta tgaggcattt gcctccaagt agcctatcct tcagaattac 1132

ttgtaggata ttcctctctt catgttctaa taaacttcta catcatca 1180

<210> 4
<211> 317
<212> PRT
<213> Mus musculus

<400> 4

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn
1 5 10 15

Ala Glu Ala Leu Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys
20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp
35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Asp Met
50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu
65 70 75 80

Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr
85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile
100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val
115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu
130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu
145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu
165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala
180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe
195 200 205

Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val
210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg His Thr Arg Gln Ala Ser Glu
225 230 235 240

Glu Asp Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met
290 295 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
305 310 315

<210> 5
<211> 1197
<212> DNA
<213> Rattus norvegicus

<220>
<221> CDS
<222> (68)..(1021)
<223>

<400> 5
actccacctc agcagtggtc tctcagtcct ctcaaagcaa ggaaagagca ctgtgtgctg 60

ggagacc atg gca aag aat cct cca gag aac tgt gag ggc tgt cac att 109
Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile
1 5 10

cta aat gca gaa gct ctg aaa tct aag aag ata cgt aaa tca ctg aag 157
Leu Asn Ala Glu Ala Leu Lys Ser Lys Lys Ile Arg Lys Ser Leu Lys
15 20 25 30

att tgt gga cta gtg ttt ggt atc ctg gcc tta act cta att gtc ctg 205
Ile Cys Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu
35 40 45

```
ttt tgg ggg agc aaa cac ttc tgg ccc gag gta tcc aag aag acc tat      253
Phe Trp Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr
            50                  55                  60

ggc atg gag cac act ttc tac agc aat ggc gag aag aag aag att tcc      301
Gly Met Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Ser
        65                  70                  75

atg gaa att gat ccc ata acc aga aca gaa ata ttc aga agt gga aat      349
Met Glu Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn
    80                  85                  90

ggc acc gat gaa aca ttg gaa gtc cat gac ttt aaa aac gga tac act      397
Gly Thr Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr
95                  100                 105                 110

ggc atc tac ttt gta ggt ctt caa aaa tgc ttt att aaa act caa atc      445
Gly Ile Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile
                115                 120                 125

aaa gtg att cct gaa ttt tct gaa cca gaa gag gaa ata gat gag aat      493
Lys Val Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn
            130                 135                 140

gaa gaa att act aca acg ttc ttt gaa cag tca gtg att tgg gtt cct      541
Glu Glu Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro
        145                 150                 155

gca gaa aag cct att gaa aac aga gac ttc ctg aaa aat tct aaa att      589
Ala Glu Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile
    160                 165                 170

ctg gag att tgc gac aat gtg act atg tac tgg atc aat ccc act cta      637
Leu Glu Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu
175                 180                 185                 190

ata gca gtt tca gaa tta cag gac ttt gag gag gat ggt gaa gat ctt      685
Ile Ala Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu
                195                 200                 205

cac ttt cct acc agc gaa aaa aaa ggg att gac cag aat gag caa tgg      733
His Phe Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp
            210                 215                 220

gtg gtc cca caa gtg aag gtg gag aag acc cgc cgc acc aga caa gca      781
Val Val Pro Gln Val Lys Val Glu Lys Thr Arg Arg Thr Arg Gln Ala
        225                 230                 235

agc gag gaa gac ctt cct gtt aat gac tat act gaa aat gga atc gaa      829
Ser Glu Glu Asp Leu Pro Val Asn Asp Tyr Thr Glu Asn Gly Ile Glu
    240                 245                 250

ttt gat ccc atg ctg gat gag aga ggt tac tgt tgt att tac tgc cgt      877
Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg
255                 260                 265                 270

cga ggc aac cgc tac tgc cgc agg gtc tgt gaa cct tta cta ggc tac      925
Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr
                275                 280                 285
```

tac cca tac ccc tac tgc tac caa gga ggt cga gtc atc tgt cgt gtc 973
Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val
290 295 300

atc atg cct tgc aac tgg tgg gtg gcc cgc atg ctt ggg aga gtc taa 1021
Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
305 310 315

taggaagttt gagtccaaat gcttaacctt ttgttagcca acatataatt aatgcatgct 1081

actccatgaa tttctgcatt tgcctccaag tagcctatcc tccagaatta tttgtaggat 1141

attcctctct tcgtgttcta ataaacgtct acatcatcat caaaaaaaaa aaaaaa 1197

<210> 6
<211> 317
<212> PRT
<213> Rattus norvegicus

<400> 6

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn
1 5 10 15

Ala Glu Ala Leu Lys Ser Lys Lys Ile Arg Lys Ser Leu Lys Ile Cys
20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp
35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Gly Met
50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Ser Met Glu
65 70 75 80

Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr
85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile
100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val
115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu
130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu
145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu
165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala
180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe
195 200 205

Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val
210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg Arg Thr Arg Gln Ala Ser Glu
225 230 235 240

Glu Asp Leu Pro Val Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met
290 295 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
305 310 315

<210> 7
<211> 27
<212> DNA
<213> Homo sapiens

<400> 7
gagaccatgg caaagaatcc tccagag 27

<210> 8
<211> 24
<212> DNA
<213> Homo sapiens

<400> 8
ttagaccctc cccagcatgc gggc 24

<210> 9
<211> 27
<212> DNA
<213> Mus musculus

<400> 9
gagaccatgg caaagaatcc tccagag 27

<210> 10
<211> 24
<212> DNA
<213> .Mus musculus

<400> 10
ttagactctc ccaagcatgc gggc 24

<210> 11
<211> 27
<212> DNA
<213> Rattus norvegicus

<400> 11
gagaccatgg caaagaatcc tccagag 27

<210> 12
<211> 24
<212> DNA
<213> Rattus norvegicus

<400> 12
ttagactctc ccaagcatgc gggc 24

<210> 13
<211> 21
<212> DNA
<213> Homo sapiens

<400> 13
gaccctcccc agcatgcggg c 21

<210> 14
<211> 21
<212> DNA
<213> Mus musculus

<400> 14
gactctccca agcatgcggg c 21

<210> 15
<211> 975
<212> DNA
<213> Homo sapiens

<220>

<221> CDS
<222> (1)..(975)
<223>

<400> 15

atg gca aag aat cct cca gag aat tgt gaa gac tgt cac att cta aat 48
Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile Leu Asn
1 5 10 15

gca gaa gct ttt aaa tcc aag aaa ata tgt aaa tca ctt aag att tgt 96
Ala Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys
20 25 30

gga ctg gtg ttt ggt atc ctg gcc cta act cta att gtc ctg ttt tgg 144
Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp
35 40 45

ggg agc aag cac ttc tgg ccg gag gta ccc aaa aaa gcc tat gac atg 192
Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr Asp Met
50 55 60

gag cac act ttc tac agc aat gga gag aag aag aag att tac atg gaa 240
Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu
65 70 75 80

att gat cct gtg acc aga act gaa ata ttc aga agc gga aat ggc act 288
Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr
85 90 95

gat gaa aca ttg gaa gta cac gac ttt aaa aac gga tac act ggc atc 336
Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile
100 105 110

tac ttc gtg ggt ctt caa aaa tgt ttt atc aaa act cag att aaa gtg 384
Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val
115 120 125

att cct gaa ttt tct gaa cca gaa gag gaa ata gat gag aat gaa gaa 432
Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu
130 135 140

att acc aca act ttc ttt gaa cag tca gtg att tgg gtc cca gca gaa 480
Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu
145 150 155 160

aag cct att gaa aac cga gat ttt ctt aaa aat tcc aaa att ctg gag 528
Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu
165 170 175

att tgt gat aac gtg acc atg tat tgg atc aat ccc act cta ata tca 576
Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ser
180 185 190

gtt tct gag tta caa gac ttt gag gag gag gga gaa gat ctt cac ttt 624
Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His Phe
195 200 205

cct gcc aac gaa aaa aaa ggg att gaa caa aat gaa cag tgg gtg gtc 672
Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val

210 215 220

cct caa gtg aaa gta gag aag acc cgt cac gcc aga caa gca agt gag 720
Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu
225 230 235 240

gaa gaa ctt cca ata aat gac tat act gaa aat gga ata gaa ttt gat 768
Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp
245 250 255

ccc atg ctg gat gag aga ggt tat tgt tgt att tac tgc cgt cga ggc 816
Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly
260 265 270

aac cgc tat tgc cgc cgc gtc tgt gaa cct tta cta ggc tac tac cca 864
Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro
275 280 285

tat cca tac tgc tac caa gga gga cga gtc atc tgt cgt gtc atc atg 912
Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met
290 295 300

cct tgt aac tgg tgg gtg gcc cgc atg ctg ggg agg gtc gct cat cat 960
Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val Ala His His
305 310 315 320

cat cat cat cat taa 975
His His His His

<210> 16
<211> 324
<212> PRT
<213> Homo sapiens

<400> 16

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile Leu Asn
1 5 10 15

Ala Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys
20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp
35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr Asp Met
50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu
65 70 75 80

Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr
85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile
100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val
115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu
130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu
145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu
165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ser
180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His Phe
195 200 205

Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val
210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu
225 230 235 240

Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met
290 295 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val Ala His His
305 310 315 320

His His His His

<210> 17
<211> 975
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)..(975)
<223>

<400> 17
atg gca aag aat cct cca gag aac tgt gag ggc tgt cac att cta aat 48
Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn
1 5 10 15

gca gaa gct ctg aaa tct aag aag ata tgt aaa tca ctg aag att tgt 96
Ala Glu Ala Leu Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys
20 25 30

gga cta gtg ttt ggt atc ctg gcc tta act cta att gtc ctg ttt tgg 144
Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp
35 40 45

ggg agc aaa cac ttc tgg ccc gag gta tcc aag aaa acc tat gac atg 192
Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Asp Met
50 55 60

gag cac act ttc tac agc aac ggc gag aag aag aag att tac atg gaa 240
Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu
65 70 75 80

att gat ccc ata acc aga aca gaa ata ttc aga agt gga aat ggc act 288
Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr
85 90 95

gat gaa aca ttg gaa gtc cat gac ttt aaa aat gga tac act ggc atc 336
Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile
100 105 110

tac ttt gta ggt ctt caa aaa tgc ttt att aaa act caa atc aaa gtg 384
Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val
115 120 125

att cct gaa ttt tct gaa cca gag gaa gaa ata gat gag aat gaa gaa 432
Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu
130 135 140

att act aca act ttc ttt gaa cag tca gtg att tgg gtt ccc gca gaa 480
Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu
145 150 155 160

aag cct att gaa aac aga gac ttc ctg aaa aat tct aaa att ctg gag 528
Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu
165 170 175

att tgc gat aat gtg acc atg tac tgg atc aat ccc act cta ata gca 576
Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala

180 185 190

gtt tca gaa tta cag gac ttt gag gag gac ggt gaa gat ctt cac ttt 624
Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe
195 200 205

cct acc agt gaa aaa aag ggg att gac cag aat gag caa tgg gtg gtc 672
Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val
210 215 220

ccg caa gtg aag gtg gag aag acc cgc cac acc aga caa gca agc gag 720
Pro Gln Val Lys Val Glu Lys Thr Arg His Thr Arg Gln Ala Ser Glu
225 230 235 240

gaa gac ctt cct ata aat gac tat act gaa aat gga att gaa ttt gac 768
Glu Asp Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp
245 250 255

cca atg ctg gat gag aga ggt tac tgt tgt att tac tgt cgt cga ggc 816
Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly
260 265 270

aac cgt tac tgc cgc cgt gtc tgt gaa cct tta cta ggc tac tac cca 864
Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro
275 280 285

tac ccc tac tgc tac caa gga ggt cga gtc atc tgt cgt gtc atc atg 912
Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met
290 295 300

cct tgc aac tgg tgg gtg gcc cgc atg ctt ggg aga gtc gct cat cat 960
Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val Ala His His
305 310 315 320

cat cat cat cat taa 975
His His His His

<210> 18
<211> 324
<212> PRT
<213> Mus musculus

<400> 18

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn
1 5 10 15

Ala Glu Ala Leu Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys
20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp
35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Asp Met
50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu
65 70 75 80

Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr
85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile
100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val
115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu
130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu
145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu
165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala
180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe
195 200 205

Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val
210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg His Thr Arg Gln Ala Ser Glu
225 230 235 240

Glu Asp Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met
290 295 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val Ala His His
305 310 315 320

His His His His

<210> 19
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> signal sequence of preprotrypsin and FLAG peptide

<220>
<221> CDS
<222> (1)..(69)
<223>

<400> 19
atg tct gca ctt ctg atc cta gct ctt gtt gga gct gca gtt gct gac 48
Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
1 5 10 15

tac aaa gac gat gac gac aag 69
Tyr Lys Asp Asp Asp Asp Lys
20

<210> 20
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> signal sequence of preprotrypsin and FLAG peptide

<400> 20

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
1 5 10 15

Tyr Lys Asp Asp Asp Asp Lys
20

<210> 21
<211> 23
<212> DNA
<213> Homo sapiens

<400> 21
gagggagaag atcttcactt tcc 23

<210> 22
<211> 432
<212> DNA
<213> Artificial Sequence

<220>
<223> signal sequence of preprotrypsin, FLAG peptide and C terminal region of ChM1L

<220>
<221> CDS
<222> (1)..(432)
<223>

<400> 22

```
atg tct gca ctt ctg atc cta gct ctt gtt gga gct gca gtt gct gac      48
Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
1               5                  10                  15

tac aaa gac gat gac gac aag ctg gaa ttc gat gag gga gaa gat ctt      96
Tyr Lys Asp Asp Asp Asp Lys Leu Glu Phe Asp Glu Gly Glu Asp Leu
            20                  25                  30

cac ttt cct gcc aac gaa aaa aaa ggg att gaa caa aat gaa cag tgg     144
His Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp
        35                  40                  45

gtg gtc cct caa gtg aaa gta gag aag acc cgt cac gcc aga caa gca     192
Val Val Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala
    50                  55                  60

agt gag gaa gaa ctt cca ata aat gac tat act gaa aat gga ata gaa     240
Ser Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu
65                  70                  75                  80

ttt gat ccc atg ctg gat gag aga ggt tat tgt tgt att tac tgc cgt     288
Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg
                85                  90                  95

cga ggc aac cgc tat tgc cgc cgc gtc tgt gaa cct tta cta ggc tac     336
Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr
            100                 105                 110

tac cca tat cca tac tgc tac caa gga gga cga gtc atc tgt cgt gtc     384
Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val
        115                 120                 125

atc atg cct tgt aac tgg tgg gtg gcc cgc atg ctg ggg agg gtc taa     432
Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
    130                 135                 140
```

<210> 23
<211> 143
<212> PRT
<213> Artificial Sequence

<220>

<223> signal sequence of preprotrypsin, FLAG peptide and C terminal reg ion of ChM1L

<400> 23

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
1 5 10 15

Tyr Lys Asp Asp Asp Asp Lys Leu Glu Phe Asp Glu Gly Glu Asp Leu
20 25 30

His Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp
35 40 45

Val Val Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala
50 55 60

Ser Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu
65 70 75 80

Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg
85 90 95

Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr
100 105 110

Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val
115 120 125

Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
130 135 140

<210> 24
<211> 21
<212> DNA
<213> Mus musculus

<400> 24
tcagccatga cagagaactc a 21

<210> 25
<211> 21
<212> DNA
<213> Mus musculus

<400> 25
ttacaccatg cccaagatgc g 21